https://trial.medpath.com/news/genmab-s-epcoritamab-shows-promising-results-in-first-line-lymphoma-treatment-with-fixed-duration-therapy 2025-12-06T17:22:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/genmab-s-epcoritamab-shows-promising-results-in-first-line-lymphoma-treatment-with-fixed-duration-therapy 2025-12-06T17:22:57+00:00 hourly 0.9 https://trial.medpath.com/news/painreform-advances-ocuring-k-phase-2-trial-for-drop-free-post-cataract-surgery-pain-management 2025-12-06T13:25:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/painreform-advances-ocuring-k-phase-2-trial-for-drop-free-post-cataract-surgery-pain-management 2025-12-06T13:25:19+00:00 hourly 0.9 https://trial.medpath.com/news/abbvie-reports-positive-phase-3-results-for-migraine-drug-atogepant-in-eclipse-trial 2025-12-06T13:25:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/abbvie-reports-positive-phase-3-results-for-migraine-drug-atogepant-in-eclipse-trial 2025-12-06T13:25:17+00:00 hourly 0.9 https://trial.medpath.com/news/lebrikizumab-shows-comparable-efficacy-to-dupilumab-in-moderate-to-severe-atopic-dermatitis-treatment 2025-12-06T13:25:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lebrikizumab-shows-comparable-efficacy-to-dupilumab-in-moderate-to-severe-atopic-dermatitis-treatment 2025-12-06T13:25:09+00:00 hourly 0.9 https://trial.medpath.com/news/world-s-first-lung-cancer-prevention-vaccine-lungvax-enters-clinical-trials-in-2026 2025-12-06T12:03:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/world-s-first-lung-cancer-prevention-vaccine-lungvax-enters-clinical-trials-in-2026 2025-12-06T12:03:00+00:00 hourly 0.9 https://trial.medpath.com/news/toripalimab-achieves-record-breaking-long-term-survival-in-advanced-nasopharyngeal-and-esophageal-cancers 2025-12-06T10:25:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/toripalimab-achieves-record-breaking-long-term-survival-in-advanced-nasopharyngeal-and-esophageal-cancers 2025-12-06T10:25:30+00:00 hourly 0.9 https://trial.medpath.com/news/uk-launches-controversial-puberty-blocker-trial-following-national-ban 2025-12-06T06:27:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uk-launches-controversial-puberty-blocker-trial-following-national-ban 2025-12-06T06:27:44+00:00 hourly 0.9 https://trial.medpath.com/news/india-reopens-pli-applications-for-critical-antibiotic-and-antiviral-drug-manufacturing 2025-12-06T06:25:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/india-reopens-pli-applications-for-critical-antibiotic-and-antiviral-drug-manufacturing 2025-12-06T06:25:17+00:00 hourly 0.9 https://trial.medpath.com/news/al-s-pharma-s-ap-101-shows-promising-survival-benefits-in-phase-2-als-trial-advancing-to-phase-3 2025-12-06T04:25:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/al-s-pharma-s-ap-101-shows-promising-survival-benefits-in-phase-2-als-trial-advancing-to-phase-3 2025-12-06T04:25:36+00:00 hourly 0.9 https://trial.medpath.com/news/tempramed-expands-temperature-controlled-medication-storage-solutions-across-europe-and-north-america 2025-12-06T04:25:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tempramed-expands-temperature-controlled-medication-storage-solutions-across-europe-and-north-america 2025-12-06T04:25:01+00:00 hourly 0.9 https://trial.medpath.com/news/french-study-validates-long-term-safety-and-efficacy-of-moderna-s-covid-19-mrna-vaccine 2025-12-06T01:27:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/french-study-validates-long-term-safety-and-efficacy-of-moderna-s-covid-19-mrna-vaccine 2025-12-06T01:27:03+00:00 hourly 0.9 https://trial.medpath.com/news/novel-treatment-combinations-show-promise-in-mantle-cell-lymphoma-trials 2025-12-06T01:26:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-treatment-combinations-show-promise-in-mantle-cell-lymphoma-trials 2025-12-06T01:26:51+00:00 hourly 0.9 https://trial.medpath.com/news/gemcitabine-intravesical-system-shows-promise-in-bcg-unresponsive-bladder-cancer-reducing-need-for-radical-cystectomy 2025-12-06T01:26:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gemcitabine-intravesical-system-shows-promise-in-bcg-unresponsive-bladder-cancer-reducing-need-for-radical-cystectomy 2025-12-06T01:26:19+00:00 hourly 0.9 https://trial.medpath.com/news/berenson-cancer-center-reports-record-13-year-survival-for-multiple-myeloma-patients-without-standard-transplant-therapy 2025-12-06T01:25:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/berenson-cancer-center-reports-record-13-year-survival-for-multiple-myeloma-patients-without-standard-transplant-therapy 2025-12-06T01:25:08+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-omisirge-as-first-cell-therapy-for-severe-aplastic-anemia 2025-12-06T01:24:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-omisirge-as-first-cell-therapy-for-severe-aplastic-anemia 2025-12-06T01:24:36+00:00 hourly 0.9 https://trial.medpath.com/news/hims-hers-enters-canadian-market-through-livewell-acquisition-targeting-generic-semaglutide-launch 2025-12-06T01:24:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hims-hers-enters-canadian-market-through-livewell-acquisition-targeting-generic-semaglutide-launch 2025-12-06T01:24:33+00:00 hourly 0.9 https://trial.medpath.com/news/boehringer-ingelheim-s-digital-therapeutic-ct-155-shows-efficacy-for-schizophrenia-negative-symptoms-in-pivotal-trial 2025-12-06T01:24:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/boehringer-ingelheim-s-digital-therapeutic-ct-155-shows-efficacy-for-schizophrenia-negative-symptoms-in-pivotal-trial 2025-12-06T01:24:27+00:00 hourly 0.9 https://trial.medpath.com/news/amneal-s-crexont-shows-significant-clinical-benefits-in-phase-4-parkinson-s-disease-study 2025-12-05T21:35:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/amneal-s-crexont-shows-significant-clinical-benefits-in-phase-4-parkinson-s-disease-study 2025-12-05T21:35:45+00:00 hourly 0.9 https://trial.medpath.com/news/perspective-therapeutics-reports-sustained-tumor-response-with-lead-212-radiopharmaceutical-in-neuroendocrine-tumors 2025-12-05T21:35:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/perspective-therapeutics-reports-sustained-tumor-response-with-lead-212-radiopharmaceutical-in-neuroendocrine-tumors 2025-12-05T21:35:00+00:00 hourly 0.9 https://trial.medpath.com/news/blueprint-medicines-reports-long-term-efficacy-data-for-ayvakit-in-systemic-mastocytosis-at-ash-2025 2025-12-05T21:34:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/blueprint-medicines-reports-long-term-efficacy-data-for-ayvakit-in-systemic-mastocytosis-at-ash-2025 2025-12-05T21:34:55+00:00 hourly 0.9 https://trial.medpath.com/news/inmune-bio-s-cordstrom-platform-featured-in-peer-reviewed-study-on-mesenchymal-stromal-cell-therapies 2025-12-05T21:34:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/inmune-bio-s-cordstrom-platform-featured-in-peer-reviewed-study-on-mesenchymal-stromal-cell-therapies 2025-12-05T21:34:21+00:00 hourly 0.9 https://trial.medpath.com/news/apeiron-s-gta182-shows-57-response-rate-in-mtap-deleted-lung-cancer-phase-1-trial 2025-12-05T21:34:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/apeiron-s-gta182-shows-57-response-rate-in-mtap-deleted-lung-cancer-phase-1-trial 2025-12-05T21:34:07+00:00 hourly 0.9 https://trial.medpath.com/news/freenome-secures-330-million-spac-deal-to-advance-multi-cancer-blood-detection-tests 2025-12-05T21:34:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/freenome-secures-330-million-spac-deal-to-advance-multi-cancer-blood-detection-tests 2025-12-05T21:34:05+00:00 hourly 0.9 https://trial.medpath.com/news/amylyx-reports-positive-safety-data-for-amx0114-in-first-in-human-als-trial 2025-12-05T21:32:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/amylyx-reports-positive-safety-data-for-amx0114-in-first-in-human-als-trial 2025-12-05T21:32:29+00:00 hourly 0.9 https://trial.medpath.com/news/imcheck-therapeutics-to-present-promising-ict01-aml-data-at-ash-2025-showing-high-remission-rates-in-first-line-treatment 2025-12-05T21:29:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/imcheck-therapeutics-to-present-promising-ict01-aml-data-at-ash-2025-showing-high-remission-rates-in-first-line-treatment 2025-12-05T21:29:43+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-eighth-denosumab-biosimilar-as-amgen-settles-patent-dispute-with-hikma-and-gedeon-richter 2025-12-05T21:29:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-eighth-denosumab-biosimilar-as-amgen-settles-patent-dispute-with-hikma-and-gedeon-richter 2025-12-05T21:29:38+00:00 hourly 0.9 https://trial.medpath.com/news/amicus-therapeutics-galafold-drives-strong-revenue-growth-amid-pending-4-8b-biomarin-acquisition 2025-12-05T21:29:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/amicus-therapeutics-galafold-drives-strong-revenue-growth-amid-pending-4-8b-biomarin-acquisition 2025-12-05T21:29:31+00:00 hourly 0.9 https://trial.medpath.com/news/medicare-part-b-premiums-to-rise-9-7-in-2026-as-cms-negotiates-cancer-drug-price-reductions 2025-12-05T21:28:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/medicare-part-b-premiums-to-rise-9-7-in-2026-as-cms-negotiates-cancer-drug-price-reductions 2025-12-05T21:28:21+00:00 hourly 0.9 https://trial.medpath.com/news/start-opens-new-early-phase-cancer-clinical-trial-unit-in-new-york-long-island 2025-12-05T21:27:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/start-opens-new-early-phase-cancer-clinical-trial-unit-in-new-york-long-island 2025-12-05T21:27:48+00:00 hourly 0.9 https://trial.medpath.com/news/corrixr-therapeutics-partners-to-develop-first-inhaled-crispr-therapy-for-lung-cancer 2025-12-05T21:27:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/corrixr-therapeutics-partners-to-develop-first-inhaled-crispr-therapy-for-lung-cancer 2025-12-05T21:27:46+00:00 hourly 0.9 https://trial.medpath.com/news/encoded-therapeutics-reports-78-seizure-reduction-with-etx101-gene-therapy-in-dravet-syndrome-trial 2025-12-05T21:27:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/encoded-therapeutics-reports-78-seizure-reduction-with-etx101-gene-therapy-in-dravet-syndrome-trial 2025-12-05T21:27:43+00:00 hourly 0.9 https://trial.medpath.com/news/prostate-cancer-pipeline-shows-robust-growth-with-150-therapies-in-development-across-multiple-companies 2025-12-05T21:27:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/prostate-cancer-pipeline-shows-robust-growth-with-150-therapies-in-development-across-multiple-companies 2025-12-05T21:27:41+00:00 hourly 0.9 https://trial.medpath.com/news/senores-pharmaceuticals-secures-philippine-fda-approval-for-10-products-across-cardiovascular-cns-and-pain-management-therapies 2025-12-05T21:27:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/senores-pharmaceuticals-secures-philippine-fda-approval-for-10-products-across-cardiovascular-cns-and-pain-management-therapies 2025-12-05T21:27:15+00:00 hourly 0.9 https://trial.medpath.com/news/gallop-oncology-s-lyt-200-shows-promising-13-2-month-survival-in-relapsed-refractory-aml-phase-1b-trial 2025-12-05T21:27:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gallop-oncology-s-lyt-200-shows-promising-13-2-month-survival-in-relapsed-refractory-aml-phase-1b-trial 2025-12-05T21:27:03+00:00 hourly 0.9 https://trial.medpath.com/news/spineguard-receives-nmpa-clearance-for-advanced-pediguard-models-in-china 2025-12-05T21:26:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/spineguard-receives-nmpa-clearance-for-advanced-pediguard-models-in-china 2025-12-05T21:26:58+00:00 hourly 0.9 https://trial.medpath.com/news/oye-therapeutics-receives-fda-clearance-to-begin-clinical-testing-of-novel-caffeine-injection-for-anesthesia-recovery 2025-12-05T21:24:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/oye-therapeutics-receives-fda-clearance-to-begin-clinical-testing-of-novel-caffeine-injection-for-anesthesia-recovery 2025-12-05T21:24:33+00:00 hourly 0.9 https://trial.medpath.com/news/biomea-fusion-s-icovamenib-shows-durable-diabetes-benefits-nine-months-after-treatment-ends 2025-12-05T17:33:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biomea-fusion-s-icovamenib-shows-durable-diabetes-benefits-nine-months-after-treatment-ends 2025-12-05T17:33:47+00:00 hourly 0.9 https://trial.medpath.com/news/medicare-drug-price-negotiations-deliver-major-savings-25-medications-to-see-reduced-costs-by-2027 2025-12-05T17:33:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/medicare-drug-price-negotiations-deliver-major-savings-25-medications-to-see-reduced-costs-by-2027 2025-12-05T17:33:44+00:00 hourly 0.9 https://trial.medpath.com/news/long-term-follow-up-confirms-sustained-benefits-of-adjuvant-pembrolizumab-in-high-risk-clear-cell-renal-cell-carcinoma 2025-12-05T17:31:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/long-term-follow-up-confirms-sustained-benefits-of-adjuvant-pembrolizumab-in-high-risk-clear-cell-renal-cell-carcinoma 2025-12-05T17:31:21+00:00 hourly 0.9 https://trial.medpath.com/news/candel-therapeutics-reports-30-reduction-in-prostate-cancer-recurrence-risk-with-can-2409-in-phase-3-trial 2025-12-05T17:31:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/candel-therapeutics-reports-30-reduction-in-prostate-cancer-recurrence-risk-with-can-2409-in-phase-3-trial 2025-12-05T17:31:19+00:00 hourly 0.9 https://trial.medpath.com/news/first-in-class-mmset-inhibitor-gintemetostat-shows-clinical-activity-in-heavily-pretreated-multiple-myeloma 2025-12-05T17:31:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/first-in-class-mmset-inhibitor-gintemetostat-shows-clinical-activity-in-heavily-pretreated-multiple-myeloma 2025-12-05T17:31:02+00:00 hourly 0.9 https://trial.medpath.com/news/first-ever-personalized-crispr-therapy-successfully-treats-baby-with-ultra-rare-metabolic-disorder 2025-12-05T17:30:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/first-ever-personalized-crispr-therapy-successfully-treats-baby-with-ultra-rare-metabolic-disorder 2025-12-05T17:30:33+00:00 hourly 0.9 https://trial.medpath.com/news/regeneron-and-tessera-therapeutics-form-global-partnership-to-advance-tsra-196-gene-writing-therapy 2025-12-05T17:30:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/regeneron-and-tessera-therapeutics-form-global-partnership-to-advance-tsra-196-gene-writing-therapy 2025-12-05T17:30:30+00:00 hourly 0.9 https://trial.medpath.com/news/roche-advances-in-tigit-immunotherapy-and-ai-driven-biomarker-development-signal-strategic-shift-in-precision-oncology 2025-12-05T17:29:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/roche-advances-in-tigit-immunotherapy-and-ai-driven-biomarker-development-signal-strategic-shift-in-precision-oncology 2025-12-05T17:29:58+00:00 hourly 0.9 https://trial.medpath.com/news/novo-nordisk-receives-fda-approval-for-oral-wegovy-formulation-driving-pharmaceutical-sector-gains 2025-12-05T17:29:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novo-nordisk-receives-fda-approval-for-oral-wegovy-formulation-driving-pharmaceutical-sector-gains 2025-12-05T17:29:53+00:00 hourly 0.9 https://trial.medpath.com/news/revalia-bio-secures-26-7-million-arpa-h-award-to-revolutionize-drug-development-with-human-data-trials 2025-12-05T17:29:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/revalia-bio-secures-26-7-million-arpa-h-award-to-revolutionize-drug-development-with-human-data-trials 2025-12-05T17:29:15+00:00 hourly 0.9 https://trial.medpath.com/news/wugen-s-allogeneic-car-t-therapy-shows-promising-long-term-survival-data-in-t-cell-leukemia-patients 2025-12-05T17:29:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/wugen-s-allogeneic-car-t-therapy-shows-promising-long-term-survival-data-in-t-cell-leukemia-patients 2025-12-05T17:29:13+00:00 hourly 0.9 https://trial.medpath.com/news/stat3-inhibitor-safety-concerns-highlight-alternative-approaches-in-ipf-drug-development 2025-12-05T17:29:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/stat3-inhibitor-safety-concerns-highlight-alternative-approaches-in-ipf-drug-development 2025-12-05T17:29:01+00:00 hourly 0.9 https://trial.medpath.com/news/palbociclib-triple-therapy-shows-significant-survival-benefit-in-her2-positive-breast-cancer-trial 2025-12-05T17:28:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/palbociclib-triple-therapy-shows-significant-survival-benefit-in-her2-positive-breast-cancer-trial 2025-12-05T17:28:20+00:00 hourly 0.9 https://trial.medpath.com/news/fda-launches-commissioner-s-national-priority-voucher-program-to-accelerate-critical-drug-reviews 2025-12-05T17:26:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-launches-commissioner-s-national-priority-voucher-program-to-accelerate-critical-drug-reviews 2025-12-05T17:26:50+00:00 hourly 0.9 https://trial.medpath.com/news/bristol-myers-squibb-s-breyanzi-becomes-first-car-t-therapy-approved-for-marginal-zone-lymphoma 2025-12-05T17:26:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bristol-myers-squibb-s-breyanzi-becomes-first-car-t-therapy-approved-for-marginal-zone-lymphoma 2025-12-05T17:26:38+00:00 hourly 0.9 https://trial.medpath.com/news/b-braun-launches-piperacillin-tazobactam-in-duplex-drug-delivery-system-to-reduce-medication-errors 2025-12-05T17:26:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/b-braun-launches-piperacillin-tazobactam-in-duplex-drug-delivery-system-to-reduce-medication-errors 2025-12-05T17:26:07+00:00 hourly 0.9 https://trial.medpath.com/news/otr-therapeutics-secures-100-million-series-a-to-build-capital-efficient-r-d-platform-in-shanghai 2025-12-05T13:32:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/otr-therapeutics-secures-100-million-series-a-to-build-capital-efficient-r-d-platform-in-shanghai 2025-12-05T13:32:19+00:00 hourly 0.9 https://trial.medpath.com/news/transcenta-s-osemitamab-combination-shows-promising-16-6-month-median-pfs-in-first-line-gastric-cancer-trial 2025-12-05T13:31:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/transcenta-s-osemitamab-combination-shows-promising-16-6-month-median-pfs-in-first-line-gastric-cancer-trial 2025-12-05T13:31:35+00:00 hourly 0.9 https://trial.medpath.com/news/rocatinlimab-demonstrates-significant-efficacy-in-phase-3-trials-for-moderate-to-severe-atopic-dermatitis 2025-12-05T13:31:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rocatinlimab-demonstrates-significant-efficacy-in-phase-3-trials-for-moderate-to-severe-atopic-dermatitis 2025-12-05T13:31:29+00:00 hourly 0.9 https://trial.medpath.com/news/hanmi-pharmaceutical-s-efeglenatide-receives-fast-track-designation-for-obesity-treatment-in-south-korea 2025-12-05T13:30:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hanmi-pharmaceutical-s-efeglenatide-receives-fast-track-designation-for-obesity-treatment-in-south-korea 2025-12-05T13:30:13+00:00 hourly 0.9 https://trial.medpath.com/news/cumulus-neuroscience-demonstrates-superior-digital-endpoints-for-alzheimer-s-clinical-trials-at-ctad-2025 2025-12-05T13:30:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cumulus-neuroscience-demonstrates-superior-digital-endpoints-for-alzheimer-s-clinical-trials-at-ctad-2025 2025-12-05T13:30:08+00:00 hourly 0.9 https://trial.medpath.com/news/alvotech-gains-european-approval-for-denosumab-biosimilar-avt03-opening-access-to-1-2-billion-market 2025-12-05T13:29:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alvotech-gains-european-approval-for-denosumab-biosimilar-avt03-opening-access-to-1-2-billion-market 2025-12-05T13:29:41+00:00 hourly 0.9 https://trial.medpath.com/news/beigene-reports-record-1-4-billion-quarterly-revenue-as-brukinsa-surpasses-1-billion-milestone 2025-12-05T12:10:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/beigene-reports-record-1-4-billion-quarterly-revenue-as-brukinsa-surpasses-1-billion-milestone 2025-12-05T12:10:43+00:00 hourly 0.9 https://trial.medpath.com/news/annexin-pharmaceuticals-reports-promising-early-results-from-phase-2a-study-of-anxv-in-diabetic-retinopathy-and-retinal-vein-occlusion 2025-12-05T12:10:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/annexin-pharmaceuticals-reports-promising-early-results-from-phase-2a-study-of-anxv-in-diabetic-retinopathy-and-retinal-vein-occlusion 2025-12-05T12:10:39+00:00 hourly 0.9 https://trial.medpath.com/news/gelteq-s-oral-gel-platform-shows-22-bioavailability-boost-for-medicinal-cannabinoids-in-preclinical-study 2025-12-05T10:29:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gelteq-s-oral-gel-platform-shows-22-bioavailability-boost-for-medicinal-cannabinoids-in-preclinical-study 2025-12-05T10:29:00+00:00 hourly 0.9 https://trial.medpath.com/news/us-fda-accepts-wockhardt-s-nda-for-novel-antibiotic-zaynich-marking-historic-first-for-indian-pharma 2025-12-05T09:52:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/us-fda-accepts-wockhardt-s-nda-for-novel-antibiotic-zaynich-marking-historic-first-for-indian-pharma 2025-12-05T09:52:16+00:00 hourly 0.9 https://trial.medpath.com/news/lupin-receives-tentative-fda-approval-for-generic-siponimod-multiple-sclerosis-treatment 2025-12-05T09:52:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lupin-receives-tentative-fda-approval-for-generic-siponimod-multiple-sclerosis-treatment 2025-12-05T09:52:01+00:00 hourly 0.9 https://trial.medpath.com/news/french-study-of-28-million-adults-confirms-long-term-safety-of-covid-19-mrna-vaccines 2025-12-05T06:09:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/french-study-of-28-million-adults-confirms-long-term-safety-of-covid-19-mrna-vaccines 2025-12-05T06:09:57+00:00 hourly 0.9 https://trial.medpath.com/news/genentech-and-roche-secure-upc-evidence-orders-against-organon-s-pertuzumab-biosimilar 2025-12-05T06:09:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/genentech-and-roche-secure-upc-evidence-orders-against-organon-s-pertuzumab-biosimilar 2025-12-05T06:09:54+00:00 hourly 0.9 https://trial.medpath.com/news/german-court-blocks-merck-s-subcutaneous-keytruda-launch-in-patent-dispute-with-halozyme 2025-12-05T06:09:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/german-court-blocks-merck-s-subcutaneous-keytruda-launch-in-patent-dispute-with-halozyme 2025-12-05T06:09:49+00:00 hourly 0.9 https://trial.medpath.com/news/fda-clears-first-in-class-bispecific-adc-ide034-for-phase-1-trial-in-multiple-solid-tumors 2025-12-05T06:09:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-clears-first-in-class-bispecific-adc-ide034-for-phase-1-trial-in-multiple-solid-tumors 2025-12-05T06:09:41+00:00 hourly 0.9 https://trial.medpath.com/news/cell-and-gene-therapy-investment-plummets-66-as-industry-shifts-to-lower-risk-strategies 2025-12-05T06:09:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cell-and-gene-therapy-investment-plummets-66-as-industry-shifts-to-lower-risk-strategies 2025-12-05T06:09:38+00:00 hourly 0.9 https://trial.medpath.com/news/ipsc-therapy-for-parkinson-s-disease-receives-fda-rmat-designation-marking-regulatory-milestone 2025-12-05T06:09:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ipsc-therapy-for-parkinson-s-disease-receives-fda-rmat-designation-marking-regulatory-milestone 2025-12-05T06:09:30+00:00 hourly 0.9 https://trial.medpath.com/news/cystic-fibrosis-patients-on-triple-drug-therapy-can-safely-reduce-daily-lung-treatments-multi-site-study-shows 2025-12-05T06:09:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cystic-fibrosis-patients-on-triple-drug-therapy-can-safely-reduce-daily-lung-treatments-multi-site-study-shows 2025-12-05T06:09:25+00:00 hourly 0.9 https://trial.medpath.com/news/ascentage-pharma-receives-fda-and-ema-clearance-for-global-phase-iii-trial-of-olverembatinib-in-philadelphia-chromosome-positive-all 2025-12-05T04:09:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ascentage-pharma-receives-fda-and-ema-clearance-for-global-phase-iii-trial-of-olverembatinib-in-philadelphia-chromosome-positive-all 2025-12-05T04:09:57+00:00 hourly 0.9 https://trial.medpath.com/news/pharmaceutical-industry-turns-to-ai-to-combat-236-billion-patent-cliff-crisis 2025-12-05T04:09:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pharmaceutical-industry-turns-to-ai-to-combat-236-billion-patent-cliff-crisis 2025-12-05T04:09:44+00:00 hourly 0.9 https://trial.medpath.com/news/ai-transforms-cancer-drug-development-from-discovery-to-clinical-management 2025-12-05T03:52:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ai-transforms-cancer-drug-development-from-discovery-to-clinical-management 2025-12-05T03:52:07+00:00 hourly 0.9 https://trial.medpath.com/news/sanofi-secures-dual-eu-approvals-dupixent-for-chronic-urticaria-and-first-ever-btk-inhibitor-wayrilz-for-immune-thrombocytopenia 2025-12-05T00:54:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sanofi-secures-dual-eu-approvals-dupixent-for-chronic-urticaria-and-first-ever-btk-inhibitor-wayrilz-for-immune-thrombocytopenia 2025-12-05T00:54:41+00:00 hourly 0.9 https://trial.medpath.com/news/fda-lifts-clinical-hold-on-tradipitant-clearing-path-for-first-new-motion-sickness-treatment-in-40-years 2025-12-05T00:54:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-lifts-clinical-hold-on-tradipitant-clearing-path-for-first-new-motion-sickness-treatment-in-40-years 2025-12-05T00:54:08+00:00 hourly 0.9 https://trial.medpath.com/news/immorta-bio-s-senovaxtm-shows-tumor-reduction-across-multiple-cancer-types-in-preclinical-study 2025-12-05T00:53:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/immorta-bio-s-senovaxtm-shows-tumor-reduction-across-multiple-cancer-types-in-preclinical-study 2025-12-05T00:53:28+00:00 hourly 0.9 https://trial.medpath.com/news/scineuro-pharmaceuticals-secures-53m-series-funding-to-advance-neurodegeneration-therapies 2025-12-05T00:51:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/scineuro-pharmaceuticals-secures-53m-series-funding-to-advance-neurodegeneration-therapies 2025-12-05T00:51:02+00:00 hourly 0.9 https://trial.medpath.com/news/nikon-instruments-and-yamaha-motor-form-strategic-partnership-to-advance-drug-discovery-research 2025-12-05T00:50:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nikon-instruments-and-yamaha-motor-form-strategic-partnership-to-advance-drug-discovery-research 2025-12-05T00:50:56+00:00 hourly 0.9 https://trial.medpath.com/news/duchenne-muscular-dystrophy-market-reaches-2-15-billion-as-pipeline-shows-promise-with-75-active-therapies 2025-12-05T00:50:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/duchenne-muscular-dystrophy-market-reaches-2-15-billion-as-pipeline-shows-promise-with-75-active-therapies 2025-12-05T00:50:54+00:00 hourly 0.9 https://trial.medpath.com/news/belite-bio-raises-350-million-in-public-offering-to-advance-stargardt-disease-treatment 2025-12-05T00:50:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/belite-bio-raises-350-million-in-public-offering-to-advance-stargardt-disease-treatment 2025-12-05T00:50:50+00:00 hourly 0.9 https://trial.medpath.com/news/foundation-medicine-reaches-historic-100-companion-diagnostic-approvals-milestone 2025-12-05T00:50:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/foundation-medicine-reaches-historic-100-companion-diagnostic-approvals-milestone 2025-12-05T00:50:39+00:00 hourly 0.9 https://trial.medpath.com/news/praxis-precision-medicines-advances-two-cns-programs-with-positive-fda-meeting-and-phase-2-results 2025-12-05T00:50:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/praxis-precision-medicines-advances-two-cns-programs-with-positive-fda-meeting-and-phase-2-results 2025-12-05T00:50:36+00:00 hourly 0.9 https://trial.medpath.com/news/praxis-precision-medicines-reports-positive-embold-study-results-for-relutrigine-in-rare-epileptic-encephalopathies 2025-12-05T00:50:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/praxis-precision-medicines-reports-positive-embold-study-results-for-relutrigine-in-rare-epileptic-encephalopathies 2025-12-05T00:50:33+00:00 hourly 0.9 https://trial.medpath.com/news/immortal-dragons-invests-in-etheros-pharmaceuticals-catalytic-antioxidant-platform-for-age-related-diseases 2025-12-05T00:50:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/immortal-dragons-invests-in-etheros-pharmaceuticals-catalytic-antioxidant-platform-for-age-related-diseases 2025-12-05T00:50:18+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-breyanzi-car-t-cell-therapy-for-relapsed-refractory-marginal-zone-lymphoma 2025-12-05T00:48:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-breyanzi-car-t-cell-therapy-for-relapsed-refractory-marginal-zone-lymphoma 2025-12-05T00:48:28+00:00 hourly 0.9 https://trial.medpath.com/news/algorae-pharmaceuticals-validates-ai-drug-discovery-platform-and-identifies-90-new-cannabidiol-combination-candidates 2025-12-05T00:48:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/algorae-pharmaceuticals-validates-ai-drug-discovery-platform-and-identifies-90-new-cannabidiol-combination-candidates 2025-12-05T00:48:22+00:00 hourly 0.9 https://trial.medpath.com/news/ossium-health-reports-promising-early-results-for-deceased-donor-bone-marrow-transplants-in-hematologic-malignancies 2025-12-05T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ossium-health-reports-promising-early-results-for-deceased-donor-bone-marrow-transplants-in-hematologic-malignancies 2025-12-05T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-advisory-panel-unanimously-rejects-johnson-johnson-s-v-wave-heart-shunt-for-heart-failure 2025-12-04T21:32:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-advisory-panel-unanimously-rejects-johnson-johnson-s-v-wave-heart-shunt-for-heart-failure 2025-12-04T21:32:06+00:00 hourly 0.9 https://trial.medpath.com/news/cdc-vaccine-advisory-committee-delays-vote-on-hepatitis-b-birth-dose-recommendation 2025-12-04T21:31:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cdc-vaccine-advisory-committee-delays-vote-on-hepatitis-b-birth-dose-recommendation 2025-12-04T21:31:43+00:00 hourly 0.9 https://trial.medpath.com/news/eli-lilly-s-mounjaro-gains-insurance-coverage-in-china-and-south-korea-expanding-global-access 2025-12-04T21:31:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eli-lilly-s-mounjaro-gains-insurance-coverage-in-china-and-south-korea-expanding-global-access 2025-12-04T21:31:06+00:00 hourly 0.9 https://trial.medpath.com/news/sglt-2-inhibitors-and-glp-1-agonists-show-promise-in-slowing-frailty-progression-in-older-diabetic-adults 2025-12-04T21:31:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sglt-2-inhibitors-and-glp-1-agonists-show-promise-in-slowing-frailty-progression-in-older-diabetic-adults 2025-12-04T21:31:03+00:00 hourly 0.9 https://trial.medpath.com/news/paxg-chemotherapy-shows-superior-event-free-survival-over-mfolfirinox-in-pancreatic-cancer-trial 2025-12-04T21:30:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/paxg-chemotherapy-shows-superior-event-free-survival-over-mfolfirinox-in-pancreatic-cancer-trial 2025-12-04T21:30:44+00:00 hourly 0.9 https://trial.medpath.com/news/dart-trial-shows-combination-immunotherapy-effective-in-rare-cancer-patients-with-brain-metastases 2025-12-04T21:30:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dart-trial-shows-combination-immunotherapy-effective-in-rare-cancer-patients-with-brain-metastases 2025-12-04T21:30:08+00:00 hourly 0.9 https://trial.medpath.com/news/absci-initiates-first-in-human-trial-of-ai-designed-antibody-abs-201-for-hair-loss-treatment 2025-12-04T21:29:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/absci-initiates-first-in-human-trial-of-ai-designed-antibody-abs-201-for-hair-loss-treatment 2025-12-04T21:29:02+00:00 hourly 0.9 https://trial.medpath.com/news/regeneration-biomedical-s-autologous-stem-cell-therapy-for-alzheimer-s-disease-advances-to-phase-2-following-positive-safety-data 2025-12-04T21:28:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/regeneration-biomedical-s-autologous-stem-cell-therapy-for-alzheimer-s-disease-advances-to-phase-2-following-positive-safety-data 2025-12-04T21:28:59+00:00 hourly 0.9 https://trial.medpath.com/news/rare-pediatric-disease-voucher-program-faces-uncertain-future-as-congressional-reauthorization-stalls 2025-12-04T21:28:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rare-pediatric-disease-voucher-program-faces-uncertain-future-as-congressional-reauthorization-stalls 2025-12-04T21:28:38+00:00 hourly 0.9 https://trial.medpath.com/news/port-delivery-system-demonstrates-7-year-vision-preservation-in-wet-amd-patients 2025-12-04T21:28:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/port-delivery-system-demonstrates-7-year-vision-preservation-in-wet-amd-patients 2025-12-04T21:28:13+00:00 hourly 0.9 https://trial.medpath.com/news/cedars-sinai-scientists-develop-first-in-class-rna-drug-ty1-to-repair-dna-and-regenerate-damaged-heart-tissue 2025-12-04T21:27:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cedars-sinai-scientists-develop-first-in-class-rna-drug-ty1-to-repair-dna-and-regenerate-damaged-heart-tissue 2025-12-04T21:27:14+00:00 hourly 0.9 https://trial.medpath.com/news/quotient-sciences-and-intrepid-labs-form-strategic-partnership-to-accelerate-ai-guided-drug-formulation-development 2025-12-04T21:25:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/quotient-sciences-and-intrepid-labs-form-strategic-partnership-to-accelerate-ai-guided-drug-formulation-development 2025-12-04T21:25:59+00:00 hourly 0.9 https://trial.medpath.com/news/protara-s-tara-002-cell-therapy-achieves-72-complete-response-rate-in-bcg-naive-bladder-cancer-patients 2025-12-04T21:25:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/protara-s-tara-002-cell-therapy-achieves-72-complete-response-rate-in-bcg-naive-bladder-cancer-patients 2025-12-04T21:25:51+00:00 hourly 0.9 https://trial.medpath.com/news/sana-biotechnology-refocuses-pipeline-on-type-1-diabetes-treatment-sc451-and-car-t-platform 2025-12-04T21:25:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sana-biotechnology-refocuses-pipeline-on-type-1-diabetes-treatment-sc451-and-car-t-platform 2025-12-04T21:25:46+00:00 hourly 0.9 https://trial.medpath.com/news/real-world-data-shows-lecanemab-could-delay-alzheimer-s-progression-by-8-3-years 2025-12-04T21:24:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/real-world-data-shows-lecanemab-could-delay-alzheimer-s-progression-by-8-3-years 2025-12-04T21:24:24+00:00 hourly 0.9 https://trial.medpath.com/news/cu-anschutz-launches-first-in-class-phase-1-trial-combining-parp-inhibitor-with-novel-wnt-pathway-modulator-for-resistant-ovarian-cancer 2025-12-04T21:23:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cu-anschutz-launches-first-in-class-phase-1-trial-combining-parp-inhibitor-with-novel-wnt-pathway-modulator-for-resistant-ovarian-cancer 2025-12-04T21:23:48+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-conditional-approval-to-merck-s-exzolt-cattle-ca1-for-new-world-screwworm-prevention-and-treatment 2025-12-04T21:23:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-conditional-approval-to-merck-s-exzolt-cattle-ca1-for-new-world-screwworm-prevention-and-treatment 2025-12-04T21:23:45+00:00 hourly 0.9 https://trial.medpath.com/news/als-association-awards-2-million-to-fund-phase-1-trials-of-two-novel-als-therapies 2025-12-04T21:23:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/als-association-awards-2-million-to-fund-phase-1-trials-of-two-novel-als-therapies 2025-12-04T21:23:37+00:00 hourly 0.9 https://trial.medpath.com/news/magnetically-controlled-microrobots-show-promise-for-precision-drug-delivery-in-preclinical-studies 2025-12-04T17:59:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/magnetically-controlled-microrobots-show-promise-for-precision-drug-delivery-in-preclinical-studies 2025-12-04T17:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/mission-bio-s-single-cell-platform-advances-biomarker-analysis-for-incyte-s-mpn-therapy-at-ash-2025 2025-12-04T17:36:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mission-bio-s-single-cell-platform-advances-biomarker-analysis-for-incyte-s-mpn-therapy-at-ash-2025 2025-12-04T17:36:52+00:00 hourly 0.9 https://trial.medpath.com/news/fda-issues-updated-patient-focused-drug-development-guidance-on-clinical-outcome-assessments 2025-12-04T17:35:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-issues-updated-patient-focused-drug-development-guidance-on-clinical-outcome-assessments 2025-12-04T17:35:40+00:00 hourly 0.9 https://trial.medpath.com/news/polyrizon-s-naloxone-hydrogel-shows-superior-nasal-adhesion-in-preclinical-study-potentially-improving-overdose-reversal 2025-12-04T17:35:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/polyrizon-s-naloxone-hydrogel-shows-superior-nasal-adhesion-in-preclinical-study-potentially-improving-overdose-reversal 2025-12-04T17:35:16+00:00 hourly 0.9 https://trial.medpath.com/news/debiopharm-initiates-phase-iii-trial-for-quarterly-acromegaly-treatment-debio-4126 2025-12-04T17:35:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/debiopharm-initiates-phase-iii-trial-for-quarterly-acromegaly-treatment-debio-4126 2025-12-04T17:35:02+00:00 hourly 0.9 https://trial.medpath.com/news/engineered-herpes-virus-shows-promise-against-treatment-resistant-glioblastoma-in-preclinical-studies 2025-12-04T17:34:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/engineered-herpes-virus-shows-promise-against-treatment-resistant-glioblastoma-in-preclinical-studies 2025-12-04T17:34:59+00:00 hourly 0.9 https://trial.medpath.com/news/replicate-bioscience-partners-with-instituto-butantan-to-advance-self-replicating-rna-rabies-vaccine-in-latin-america 2025-12-04T17:33:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/replicate-bioscience-partners-with-instituto-butantan-to-advance-self-replicating-rna-rabies-vaccine-in-latin-america 2025-12-04T17:33:08+00:00 hourly 0.9 https://trial.medpath.com/news/gt-biopharma-advances-gtb-3650-to-higher-dose-level-in-phase-1-blood-cancer-trial 2025-12-04T17:32:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gt-biopharma-advances-gtb-3650-to-higher-dose-level-in-phase-1-blood-cancer-trial 2025-12-04T17:32:40+00:00 hourly 0.9 https://trial.medpath.com/news/galmed-secures-global-patent-protection-for-aramchol-rezdiffra-combination-therapy-in-mash-treatment 2025-12-04T17:32:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/galmed-secures-global-patent-protection-for-aramchol-rezdiffra-combination-therapy-in-mash-treatment 2025-12-04T17:32:33+00:00 hourly 0.9 https://trial.medpath.com/news/luspatercept-shows-survival-advantage-over-esa-in-low-risk-mds-after-three-years 2025-12-04T17:31:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/luspatercept-shows-survival-advantage-over-esa-in-low-risk-mds-after-three-years 2025-12-04T17:31:26+00:00 hourly 0.9 https://trial.medpath.com/news/breakthrough-strategy-overcomes-immunotherapy-resistance-in-estrogen-receptor-positive-breast-cancer 2025-12-04T17:31:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/breakthrough-strategy-overcomes-immunotherapy-resistance-in-estrogen-receptor-positive-breast-cancer 2025-12-04T17:31:23+00:00 hourly 0.9 https://trial.medpath.com/news/alpha-9-oncology-initiates-phase-1-trial-of-novel-actinium-225-radiotherapeutic-for-melanoma 2025-12-04T17:29:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alpha-9-oncology-initiates-phase-1-trial-of-novel-actinium-225-radiotherapeutic-for-melanoma 2025-12-04T17:29:45+00:00 hourly 0.9 https://trial.medpath.com/news/volitionrx-s-sepsis-biomarker-selected-for-eur6-3-million-french-national-healthcare-initiative 2025-12-04T17:29:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/volitionrx-s-sepsis-biomarker-selected-for-eur6-3-million-french-national-healthcare-initiative 2025-12-04T17:29:37+00:00 hourly 0.9 https://trial.medpath.com/news/jyong-biotech-signs-mou-with-vietnamese-distributor-to-explore-mcs-2-market-entry 2025-12-04T17:29:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/jyong-biotech-signs-mou-with-vietnamese-distributor-to-explore-mcs-2-market-entry 2025-12-04T17:29:34+00:00 hourly 0.9 https://trial.medpath.com/news/sctbio-and-fortrea-form-strategic-partnership-to-accelerate-cell-and-gene-therapy-development 2025-12-04T17:29:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sctbio-and-fortrea-form-strategic-partnership-to-accelerate-cell-and-gene-therapy-development 2025-12-04T17:29:29+00:00 hourly 0.9 https://trial.medpath.com/news/orano-med-and-roche-advance-novel-two-step-radioimmunotherapy-targeting-cea-positive-cancers 2025-12-04T17:27:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/orano-med-and-roche-advance-novel-two-step-radioimmunotherapy-targeting-cea-positive-cancers 2025-12-04T17:27:26+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-plozasiran-for-familial-chylomicronemia-syndrome-marking-breakthrough-in-rare-lipid-disorder-treatment 2025-12-04T17:26:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-plozasiran-for-familial-chylomicronemia-syndrome-marking-breakthrough-in-rare-lipid-disorder-treatment 2025-12-04T17:26:45+00:00 hourly 0.9 https://trial.medpath.com/news/esperare-secures-gates-foundation-grant-to-develop-novel-preeclampsia-therapy 2025-12-04T17:26:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/esperare-secures-gates-foundation-grant-to-develop-novel-preeclampsia-therapy 2025-12-04T17:26:39+00:00 hourly 0.9 https://trial.medpath.com/news/bioage-labs-reports-positive-phase-1-data-for-brain-penetrant-nlrp3-inhibitor-bge-102 2025-12-04T17:26:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bioage-labs-reports-positive-phase-1-data-for-brain-penetrant-nlrp3-inhibitor-bge-102 2025-12-04T17:26:37+00:00 hourly 0.9 https://trial.medpath.com/news/j-d-pharmaceuticals-receives-fda-orphan-drug-designation-for-hepatocellular-carcinoma-treatment 2025-12-04T17:25:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/j-d-pharmaceuticals-receives-fda-orphan-drug-designation-for-hepatocellular-carcinoma-treatment 2025-12-04T17:25:43+00:00 hourly 0.9 https://trial.medpath.com/news/bd-and-chemoglo-partner-to-enhance-hazardous-drug-contamination-testing-in-healthcare-facilities 2025-12-04T17:25:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bd-and-chemoglo-partner-to-enhance-hazardous-drug-contamination-testing-in-healthcare-facilities 2025-12-04T17:25:38+00:00 hourly 0.9 https://trial.medpath.com/news/merakris-therapeutics-achieves-fda-alignment-on-mtx-001-development-pathway-for-chronic-venous-leg-ulcers 2025-12-04T17:25:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/merakris-therapeutics-achieves-fda-alignment-on-mtx-001-development-pathway-for-chronic-venous-leg-ulcers 2025-12-04T17:25:35+00:00 hourly 0.9 https://trial.medpath.com/news/italian-no-cut-trial-shows-nonoperative-management-safe-for-rectal-cancer-patients-after-complete-response 2025-12-04T17:24:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/italian-no-cut-trial-shows-nonoperative-management-safe-for-rectal-cancer-patients-after-complete-response 2025-12-04T17:24:56+00:00 hourly 0.9 https://trial.medpath.com/news/microbiota-therapy-maat013-achieves-62-response-rate-in-refractory-gi-agvhd-phase-3-trial 2025-12-04T17:24:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/microbiota-therapy-maat013-achieves-62-response-rate-in-refractory-gi-agvhd-phase-3-trial 2025-12-04T17:24:51+00:00 hourly 0.9 https://trial.medpath.com/news/fda-proposes-higher-user-fees-for-overseas-phase-i-trials-to-boost-domestic-drug-development 2025-12-04T17:24:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-proposes-higher-user-fees-for-overseas-phase-i-trials-to-boost-domestic-drug-development 2025-12-04T17:24:23+00:00 hourly 0.9 https://trial.medpath.com/news/malawi-becomes-fourth-african-nation-to-approve-lenacapavir-gilead-s-twice-yearly-hiv-prevention-injectable 2025-12-04T17:24:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/malawi-becomes-fourth-african-nation-to-approve-lenacapavir-gilead-s-twice-yearly-hiv-prevention-injectable 2025-12-04T17:24:21+00:00 hourly 0.9 https://trial.medpath.com/news/hope-medicine-s-hmi-115-receives-fda-fast-track-designation-for-endometriosis-pain-treatment 2025-12-04T17:23:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hope-medicine-s-hmi-115-receives-fda-fast-track-designation-for-endometriosis-pain-treatment 2025-12-04T17:23:48+00:00 hourly 0.9 https://trial.medpath.com/news/paradigm-health-secures-78-million-series-b-to-expand-ai-powered-clinical-trial-platform-across-us-healthcare-systems 2025-12-04T17:21:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/paradigm-health-secures-78-million-series-b-to-expand-ai-powered-clinical-trial-platform-across-us-healthcare-systems 2025-12-04T17:21:59+00:00 hourly 0.9 https://trial.medpath.com/news/terasaki-institute-develops-organ-on-chip-platform-to-test-cancer-vaccines-in-aging-populations 2025-12-04T14:05:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/terasaki-institute-develops-organ-on-chip-platform-to-test-cancer-vaccines-in-aging-populations 2025-12-04T14:05:00+00:00 hourly 0.9 https://trial.medpath.com/news/oral-glp-1-obesity-drugs-set-to-transform-korean-market-as-eli-lilly-and-novo-nordisk-advance-next-generation-therapies 2025-12-04T13:31:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/oral-glp-1-obesity-drugs-set-to-transform-korean-market-as-eli-lilly-and-novo-nordisk-advance-next-generation-therapies 2025-12-04T13:31:30+00:00 hourly 0.9 https://trial.medpath.com/news/brazil-approves-world-s-first-single-dose-dengue-vaccine-following-severe-2024-outbreak 2025-12-04T13:31:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/brazil-approves-world-s-first-single-dose-dengue-vaccine-following-severe-2024-outbreak 2025-12-04T13:31:22+00:00 hourly 0.9 https://trial.medpath.com/news/denali-therapeutics-secures-275-million-royalty-deal-with-royalty-pharma-for-hunter-syndrome-therapy 2025-12-04T13:30:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/denali-therapeutics-secures-275-million-royalty-deal-with-royalty-pharma-for-hunter-syndrome-therapy 2025-12-04T13:30:42+00:00 hourly 0.9 https://trial.medpath.com/news/labgenius-and-sanofi-expand-ai-driven-antibody-partnership-with-new-nanobody-optimization-collaboration 2025-12-04T13:30:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/labgenius-and-sanofi-expand-ai-driven-antibody-partnership-with-new-nanobody-optimization-collaboration 2025-12-04T13:30:36+00:00 hourly 0.9 https://trial.medpath.com/news/kelun-biotech-and-crescent-biopharma-form-strategic-partnership-to-advance-novel-oncology-therapeutics 2025-12-04T13:30:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kelun-biotech-and-crescent-biopharma-form-strategic-partnership-to-advance-novel-oncology-therapeutics 2025-12-04T13:30:31+00:00 hourly 0.9 https://trial.medpath.com/news/formycon-partners-with-ms-pharma-for-keytruda-biosimilar-fyb206-commercialization-in-mena-region 2025-12-04T13:30:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/formycon-partners-with-ms-pharma-for-keytruda-biosimilar-fyb206-commercialization-in-mena-region 2025-12-04T13:30:18+00:00 hourly 0.9 https://trial.medpath.com/news/mabxience-and-hp-develop-ai-powered-digital-twin-for-monoclonal-antibody-manufacturing 2025-12-04T13:29:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mabxience-and-hp-develop-ai-powered-digital-twin-for-monoclonal-antibody-manufacturing 2025-12-04T13:29:35+00:00 hourly 0.9 https://trial.medpath.com/news/iqvia-partners-with-aws-to-launch-agentic-ai-platform-for-clinical-trial-automation 2025-12-04T13:29:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/iqvia-partners-with-aws-to-launch-agentic-ai-platform-for-clinical-trial-automation 2025-12-04T13:29:23+00:00 hourly 0.9 https://trial.medpath.com/news/dupilumab-significantly-improves-quality-of-life-in-chronic-spontaneous-urticaria-patients 2025-12-04T13:29:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dupilumab-significantly-improves-quality-of-life-in-chronic-spontaneous-urticaria-patients 2025-12-04T13:29:18+00:00 hourly 0.9 https://trial.medpath.com/news/sanofi-completes-acquisition-of-vicebio-expanding-respiratory-vaccine-portfolio-with-molecular-clamp-technology 2025-12-04T13:29:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sanofi-completes-acquisition-of-vicebio-expanding-respiratory-vaccine-portfolio-with-molecular-clamp-technology 2025-12-04T13:29:06+00:00 hourly 0.9 https://trial.medpath.com/news/oxford-begins-first-in-human-trial-of-lassa-fever-vaccine-using-covid-19-platform-technology 2025-12-04T13:27:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/oxford-begins-first-in-human-trial-of-lassa-fever-vaccine-using-covid-19-platform-technology 2025-12-04T13:27:57+00:00 hourly 0.9 https://trial.medpath.com/news/laigo-bio-secures-eur11-5-million-to-advance-novel-protein-degradation-platform-for-cancer-and-autoimmune-diseases 2025-12-04T13:27:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/laigo-bio-secures-eur11-5-million-to-advance-novel-protein-degradation-platform-for-cancer-and-autoimmune-diseases 2025-12-04T13:27:51+00:00 hourly 0.9 https://trial.medpath.com/news/actithera-appoints-radiopharmaceutical-veteran-dr-darshan-dalal-as-chief-medical-officer-to-lead-fap-targeting-therapy-development 2025-12-04T13:27:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/actithera-appoints-radiopharmaceutical-veteran-dr-darshan-dalal-as-chief-medical-officer-to-lead-fap-targeting-therapy-development 2025-12-04T13:27:46+00:00 hourly 0.9 https://trial.medpath.com/news/monte-rosa-therapeutics-reports-promising-mrt-8102-cardiovascular-data-and-prepares-updated-mrt-2359-cancer-results 2025-12-04T13:27:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/monte-rosa-therapeutics-reports-promising-mrt-8102-cardiovascular-data-and-prepares-updated-mrt-2359-cancer-results 2025-12-04T13:27:37+00:00 hourly 0.9 https://trial.medpath.com/news/lupin-partners-with-valorum-biologics-for-us-launch-of-cancer-biosimilar-armlupeg 2025-12-04T13:26:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lupin-partners-with-valorum-biologics-for-us-launch-of-cancer-biosimilar-armlupeg 2025-12-04T13:26:33+00:00 hourly 0.9 https://trial.medpath.com/news/bayer-initiates-phase-iia-trial-for-novel-alport-syndrome-treatment-bay-3401016 2025-12-04T13:26:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bayer-initiates-phase-iia-trial-for-novel-alport-syndrome-treatment-bay-3401016 2025-12-04T13:26:30+00:00 hourly 0.9 https://trial.medpath.com/news/ionctura-initiates-phase-i-ii-trial-combining-roginolisib-with-ruxolitinib-for-jak-inhibitor-resistant-myelofibrosis 2025-12-04T13:26:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ionctura-initiates-phase-i-ii-trial-combining-roginolisib-with-ruxolitinib-for-jak-inhibitor-resistant-myelofibrosis 2025-12-04T13:26:05+00:00 hourly 0.9 https://trial.medpath.com/news/garsorasib-shows-45-5-response-rate-in-kras-g12c-mutated-pancreatic-cancer-patients 2025-12-04T13:26:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/garsorasib-shows-45-5-response-rate-in-kras-g12c-mutated-pancreatic-cancer-patients 2025-12-04T13:26:02+00:00 hourly 0.9 https://trial.medpath.com/news/avencell-therapeutics-receives-fda-and-ema-clearance-for-phase-i-ii-trial-of-dual-target-allogeneic-car-t-therapy 2025-12-04T13:25:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/avencell-therapeutics-receives-fda-and-ema-clearance-for-phase-i-ii-trial-of-dual-target-allogeneic-car-t-therapy 2025-12-04T13:25:55+00:00 hourly 0.9 https://trial.medpath.com/news/fda-announces-shift-to-single-trial-standard-for-drug-approvals-under-new-commissioner-makary 2025-12-04T13:25:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-announces-shift-to-single-trial-standard-for-drug-approvals-under-new-commissioner-makary 2025-12-04T13:25:53+00:00 hourly 0.9 https://trial.medpath.com/news/atavistik-bio-unveils-novel-jak2-v617f-mutant-selective-inhibitors-for-myeloproliferative-neoplasms-at-ash-2025 2025-12-04T12:12:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/atavistik-bio-unveils-novel-jak2-v617f-mutant-selective-inhibitors-for-myeloproliferative-neoplasms-at-ash-2025 2025-12-04T12:12:00+00:00 hourly 0.9 https://trial.medpath.com/news/insilico-medicine-raises-295-million-in-hong-kong-ipo-as-ai-drug-discovery-gains-momentum 2025-12-04T11:06:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/insilico-medicine-raises-295-million-in-hong-kong-ipo-as-ai-drug-discovery-gains-momentum 2025-12-04T11:06:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-advances-new-approach-methodologies-to-reduce-animal-testing-in-drug-development 2025-12-04T10:13:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-advances-new-approach-methodologies-to-reduce-animal-testing-in-drug-development 2025-12-04T10:13:00+00:00 hourly 0.9 https://trial.medpath.com/news/cms-proposes-major-medicare-advantage-and-part-d-reforms-for-2027-streamlining-star-ratings-and-drug-coverage-programs 2025-12-04T09:26:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cms-proposes-major-medicare-advantage-and-part-d-reforms-for-2027-streamlining-star-ratings-and-drug-coverage-programs 2025-12-04T09:26:55+00:00 hourly 0.9 https://trial.medpath.com/news/former-fda-and-cdc-leaders-warn-against-proposed-vaccine-policy-changes-amid-acip-deliberations 2025-12-04T09:26:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/former-fda-and-cdc-leaders-warn-against-proposed-vaccine-policy-changes-amid-acip-deliberations 2025-12-04T09:26:28+00:00 hourly 0.9 https://trial.medpath.com/news/federal-court-of-appeal-upholds-trademark-injunction-against-samsung-bioepis-byooviz-biosimilar 2025-12-04T09:25:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/federal-court-of-appeal-upholds-trademark-injunction-against-samsung-bioepis-byooviz-biosimilar 2025-12-04T09:25:50+00:00 hourly 0.9 https://trial.medpath.com/news/hiropharmaconsulting-receives-japan-s-first-patent-for-ai-enabled-pharmacovigilance-system-validation 2025-12-04T09:25:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hiropharmaconsulting-receives-japan-s-first-patent-for-ai-enabled-pharmacovigilance-system-validation 2025-12-04T09:25:44+00:00 hourly 0.9 https://trial.medpath.com/news/argenica-s-arg-007-shows-promise-for-severe-stroke-patients-while-demonstrating-safety-compatibility-with-standard-clot-dissolving-therapies 2025-12-04T09:25:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/argenica-s-arg-007-shows-promise-for-severe-stroke-patients-while-demonstrating-safety-compatibility-with-standard-clot-dissolving-therapies 2025-12-04T09:25:41+00:00 hourly 0.9 https://trial.medpath.com/news/novartis-establishes-india-as-largest-r-d-hub-outside-switzerland-with-9000-strong-workforce 2025-12-04T09:25:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novartis-establishes-india-as-largest-r-d-hub-outside-switzerland-with-9000-strong-workforce 2025-12-04T09:25:32+00:00 hourly 0.9 https://trial.medpath.com/news/fda-proposes-major-overhaul-of-biosimilar-approval-process-eliminating-most-clinical-studies 2025-12-04T09:25:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-proposes-major-overhaul-of-biosimilar-approval-process-eliminating-most-clinical-studies 2025-12-04T09:25:26+00:00 hourly 0.9 https://trial.medpath.com/news/liver-cirrhosis-pipeline-shows-strong-growth-with-30-companies-advancing-novel-therapies-through-clinical-trials 2025-12-04T07:10:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/liver-cirrhosis-pipeline-shows-strong-growth-with-30-companies-advancing-novel-therapies-through-clinical-trials 2025-12-04T07:10:00+00:00 hourly 0.9 https://trial.medpath.com/news/altimmune-announces-ceo-transition-as-pemvidutide-approaches-phase-3-readiness 2025-12-04T06:40:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/altimmune-announces-ceo-transition-as-pemvidutide-approaches-phase-3-readiness 2025-12-04T06:40:46+00:00 hourly 0.9 https://trial.medpath.com/news/biontech-completes-curevac-acquisition-with-81-74-shareholder-acceptance-consolidating-mrna-technology-portfolio 2025-12-04T06:39:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biontech-completes-curevac-acquisition-with-81-74-shareholder-acceptance-consolidating-mrna-technology-portfolio 2025-12-04T06:39:09+00:00 hourly 0.9 https://trial.medpath.com/news/transthera-s-tinengotinib-receives-priority-review-status-in-china-for-advanced-cholangiocarcinoma-treatment 2025-12-04T06:39:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/transthera-s-tinengotinib-receives-priority-review-status-in-china-for-advanced-cholangiocarcinoma-treatment 2025-12-04T06:39:06+00:00 hourly 0.9 https://trial.medpath.com/news/novabridge-s-ragistomig-shows-promise-in-checkpoint-inhibitor-resistant-cancers-with-new-q6w-dosing-schedule 2025-12-04T06:38:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novabridge-s-ragistomig-shows-promise-in-checkpoint-inhibitor-resistant-cancers-with-new-q6w-dosing-schedule 2025-12-04T06:38:47+00:00 hourly 0.9 https://trial.medpath.com/news/vera-therapeutics-reports-positive-phase-3-igan-data-prompting-valuation-reassessment 2025-12-04T06:38:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vera-therapeutics-reports-positive-phase-3-igan-data-prompting-valuation-reassessment 2025-12-04T06:38:44+00:00 hourly 0.9 https://trial.medpath.com/news/nona-biosciences-appoints-dr-hongjiang-miao-as-chief-ai-officer-to-advance-ai-driven-drug-discovery-strategy 2025-12-04T06:38:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nona-biosciences-appoints-dr-hongjiang-miao-as-chief-ai-officer-to-advance-ai-driven-drug-discovery-strategy 2025-12-04T06:38:30+00:00 hourly 0.9 https://trial.medpath.com/news/impact-biotech-reports-70-complete-response-rate-in-phase-3-enlighted-trial-of-padeliporfin-vtp-for-low-grade-upper-tract-urothelial-cancer 2025-12-04T06:38:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/impact-biotech-reports-70-complete-response-rate-in-phase-3-enlighted-trial-of-padeliporfin-vtp-for-low-grade-upper-tract-urothelial-cancer 2025-12-04T06:38:22+00:00 hourly 0.9 https://trial.medpath.com/news/celltrion-s-ct-p70-adc-receives-fda-fast-track-designation-for-metastatic-lung-cancer 2025-12-04T06:38:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/celltrion-s-ct-p70-adc-receives-fda-fast-track-designation-for-metastatic-lung-cancer 2025-12-04T06:38:19+00:00 hourly 0.9 https://trial.medpath.com/news/axogen-receives-fda-biologics-license-approval-for-avance-nerve-allograft-marking-regulatory-milestone 2025-12-04T06:37:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/axogen-receives-fda-biologics-license-approval-for-avance-nerve-allograft-marking-regulatory-milestone 2025-12-04T06:37:47+00:00 hourly 0.9 https://trial.medpath.com/news/ucsf-study-shows-promise-for-hiv-functional-cure-through-triple-immunotherapy-approach 2025-12-04T06:37:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ucsf-study-shows-promise-for-hiv-functional-cure-through-triple-immunotherapy-approach 2025-12-04T06:37:29+00:00 hourly 0.9 https://trial.medpath.com/news/janx007-demonstrates-promising-efficacy-and-manageable-safety-profile-in-phase-1-metastatic-prostate-cancer-trial 2025-12-04T06:36:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/janx007-demonstrates-promising-efficacy-and-manageable-safety-profile-in-phase-1-metastatic-prostate-cancer-trial 2025-12-04T06:36:58+00:00 hourly 0.9 https://trial.medpath.com/news/exmoor-pharma-and-ucl-form-strategic-partnership-to-accelerate-cell-and-gene-therapy-development 2025-12-04T06:36:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/exmoor-pharma-and-ucl-form-strategic-partnership-to-accelerate-cell-and-gene-therapy-development 2025-12-04T06:36:24+00:00 hourly 0.9 https://trial.medpath.com/news/fda-accepts-mannkind-s-readyflow-autoinjector-application-for-rapid-furosemide-delivery-in-heart-failure 2025-12-04T06:33:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-accepts-mannkind-s-readyflow-autoinjector-application-for-rapid-furosemide-delivery-in-heart-failure 2025-12-04T06:33:56+00:00 hourly 0.9 https://trial.medpath.com/news/larkspur-biosciences-initiates-first-in-human-trial-of-novel-protein-degrader-lrk-4189-for-colorectal-cancer 2025-12-04T06:33:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/larkspur-biosciences-initiates-first-in-human-trial-of-novel-protein-degrader-lrk-4189-for-colorectal-cancer 2025-12-04T06:33:54+00:00 hourly 0.9 https://trial.medpath.com/news/gensight-biologics-secures-french-regulatory-approvals-for-gs010-lumevoq-gene-therapy-in-rare-blindness-disease 2025-12-04T06:32:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gensight-biologics-secures-french-regulatory-approvals-for-gs010-lumevoq-gene-therapy-in-rare-blindness-disease 2025-12-04T06:32:19+00:00 hourly 0.9 https://trial.medpath.com/news/lyric-bio-raises-6-6m-to-revolutionize-ivig-production-with-ultra-high-density-bioreactors 2025-12-04T06:32:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lyric-bio-raises-6-6m-to-revolutionize-ivig-production-with-ultra-high-density-bioreactors 2025-12-04T06:32:13+00:00 hourly 0.9 https://trial.medpath.com/news/bayer-launches-phase-iii-trial-testing-mirena-iud-for-precancerous-uterine-condition-with-no-approved-treatments 2025-12-04T06:32:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bayer-launches-phase-iii-trial-testing-mirena-iud-for-precancerous-uterine-condition-with-no-approved-treatments 2025-12-04T06:32:04+00:00 hourly 0.9 https://trial.medpath.com/news/alpha-tau-receives-fda-approval-for-prostate-cancer-trial-and-presents-pancreatic-cancer-data-at-asco 2025-12-04T06:31:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alpha-tau-receives-fda-approval-for-prostate-cancer-trial-and-presents-pancreatic-cancer-data-at-asco 2025-12-04T06:31:44+00:00 hourly 0.9 https://trial.medpath.com/news/tscan-therapeutics-announces-two-year-relapse-data-for-tsc-101-cell-therapy-ahead-of-pivotal-trial-launch 2025-12-04T06:31:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tscan-therapeutics-announces-two-year-relapse-data-for-tsc-101-cell-therapy-ahead-of-pivotal-trial-launch 2025-12-04T06:31:09+00:00 hourly 0.9 https://trial.medpath.com/news/dogwood-therapeutics-secures-26-8m-financing-and-files-new-ip-protection-for-synthetic-halneuron-through-2045 2025-12-04T06:30:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dogwood-therapeutics-secures-26-8m-financing-and-files-new-ip-protection-for-synthetic-halneuron-through-2045 2025-12-04T06:30:35+00:00 hourly 0.9 https://trial.medpath.com/news/advanced-solid-dispersion-techniques-show-promise-for-improving-tegoprazan-bioavailability-in-gerd-treatment 2025-12-04T06:30:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/advanced-solid-dispersion-techniques-show-promise-for-improving-tegoprazan-bioavailability-in-gerd-treatment 2025-12-04T06:30:18+00:00 hourly 0.9 https://trial.medpath.com/news/quralis-demonstrates-target-engagement-of-qrl-101-in-als-patients-advancing-precision-medicine-for-neurological-disorders 2025-12-04T06:29:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/quralis-demonstrates-target-engagement-of-qrl-101-in-als-patients-advancing-precision-medicine-for-neurological-disorders 2025-12-04T06:29:32+00:00 hourly 0.9 https://trial.medpath.com/news/soligenix-advances-hybryte-through-final-phase-3-trial-for-rare-cutaneous-t-cell-lymphoma 2025-12-04T06:27:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/soligenix-advances-hybryte-through-final-phase-3-trial-for-rare-cutaneous-t-cell-lymphoma 2025-12-04T06:27:28+00:00 hourly 0.9 https://trial.medpath.com/news/immutep-s-eftilagimod-alfa-shows-strong-response-rates-in-metastatic-breast-cancer-establishes-optimal-dose-for-future-trials 2025-12-04T06:27:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/immutep-s-eftilagimod-alfa-shows-strong-response-rates-in-metastatic-breast-cancer-establishes-optimal-dose-for-future-trials 2025-12-04T06:27:13+00:00 hourly 0.9 https://trial.medpath.com/news/scholar-rock-faces-manufacturing-setback-as-fda-issues-warning-letter-to-catalent-partner-ahead-of-apitegromab-launch 2025-12-04T06:26:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/scholar-rock-faces-manufacturing-setback-as-fda-issues-warning-letter-to-catalent-partner-ahead-of-apitegromab-launch 2025-12-04T06:26:02+00:00 hourly 0.9 https://trial.medpath.com/news/ventyx-expands-phase-2-recurrent-pericarditis-trial-internationally-adds-industry-veterans-to-advisory-board 2025-12-04T06:26:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ventyx-expands-phase-2-recurrent-pericarditis-trial-internationally-adds-industry-veterans-to-advisory-board 2025-12-04T06:26:00+00:00 hourly 0.9 https://trial.medpath.com/news/australian-court-rules-formulation-patents-ineligible-for-patent-term-extensions-in-landmark-otsuka-decision 2025-12-04T06:23:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/australian-court-rules-formulation-patents-ineligible-for-patent-term-extensions-in-landmark-otsuka-decision 2025-12-04T06:23:09+00:00 hourly 0.9 https://trial.medpath.com/news/major-mid-atlantic-insurer-expands-coverage-for-nerivio-migraine-device-providing-access-to-3-4-million-members 2025-12-04T06:23:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/major-mid-atlantic-insurer-expands-coverage-for-nerivio-migraine-device-providing-access-to-3-4-million-members 2025-12-04T06:23:06+00:00 hourly 0.9 https://trial.medpath.com/news/novo-nordisk-s-cagrisema-outperforms-ozempic-in-diabetes-trial-company-plans-pediatric-obesity-study 2025-12-04T06:23:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novo-nordisk-s-cagrisema-outperforms-ozempic-in-diabetes-trial-company-plans-pediatric-obesity-study 2025-12-04T06:23:03+00:00 hourly 0.9 https://trial.medpath.com/news/ovid-therapeutics-reports-first-in-human-safety-data-for-novel-kcc2-direct-activator-ov350 2025-12-04T06:22:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ovid-therapeutics-reports-first-in-human-safety-data-for-novel-kcc2-direct-activator-ov350 2025-12-04T06:22:55+00:00 hourly 0.9 https://trial.medpath.com/news/next-generation-her2-targeted-adcs-show-promise-in-breast-cancer-trials 2025-12-04T06:20:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/next-generation-her2-targeted-adcs-show-promise-in-breast-cancer-trials 2025-12-04T06:20:15+00:00 hourly 0.9 https://trial.medpath.com/news/bayer-s-low-dose-mri-contrast-agent-gadoquatrane-shows-promise-in-pediatric-study 2025-12-04T06:20:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bayer-s-low-dose-mri-contrast-agent-gadoquatrane-shows-promise-in-pediatric-study 2025-12-04T06:20:04+00:00 hourly 0.9 https://trial.medpath.com/news/lithium-shows-promise-in-suppressing-hiv-reactivation-through-novel-mechanism 2025-12-04T06:19:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lithium-shows-promise-in-suppressing-hiv-reactivation-through-novel-mechanism 2025-12-04T06:19:39+00:00 hourly 0.9 https://trial.medpath.com/news/junevity-raises-20m-to-advance-first-in-class-sirna-cell-reprogramming-therapy-for-metabolic-disorders 2025-12-04T06:16:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/junevity-raises-20m-to-advance-first-in-class-sirna-cell-reprogramming-therapy-for-metabolic-disorders 2025-12-04T06:16:54+00:00 hourly 0.9 https://trial.medpath.com/news/experimental-vaccine-provides-year-long-protection-against-deadly-allergic-reactions-in-mice 2025-12-04T06:16:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/experimental-vaccine-provides-year-long-protection-against-deadly-allergic-reactions-in-mice 2025-12-04T06:16:40+00:00 hourly 0.9 https://trial.medpath.com/news/aspire-biopharma-advances-sublingual-aspirin-for-heart-attack-treatment-with-fda-pre-ind-submission 2025-12-04T06:15:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aspire-biopharma-advances-sublingual-aspirin-for-heart-attack-treatment-with-fda-pre-ind-submission 2025-12-04T06:15:21+00:00 hourly 0.9 https://trial.medpath.com/news/ultragenyx-advances-multiple-gene-therapies-toward-regulatory-approval-with-dtx401-bla-submission 2025-12-04T06:15:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ultragenyx-advances-multiple-gene-therapies-toward-regulatory-approval-with-dtx401-bla-submission 2025-12-04T06:15:10+00:00 hourly 0.9 https://trial.medpath.com/news/robust-aml-clinical-pipeline-shows-promise-with-100-companies-developing-novel-therapies 2025-12-04T06:14:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/robust-aml-clinical-pipeline-shows-promise-with-100-companies-developing-novel-therapies 2025-12-04T06:14:21+00:00 hourly 0.9 https://trial.medpath.com/news/foresight-diagnostics-showcases-ultrasensitive-mrd-technology-in-multiple-lymphoma-studies-at-ash-2025 2025-12-04T06:14:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/foresight-diagnostics-showcases-ultrasensitive-mrd-technology-in-multiple-lymphoma-studies-at-ash-2025 2025-12-04T06:14:18+00:00 hourly 0.9 https://trial.medpath.com/news/ge-healthcare-and-mayo-clinic-launch-gemini-rt-initiative-to-transform-personalized-radiation-therapy 2025-12-04T06:14:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ge-healthcare-and-mayo-clinic-launch-gemini-rt-initiative-to-transform-personalized-radiation-therapy 2025-12-04T06:14:16+00:00 hourly 0.9 https://trial.medpath.com/news/real-world-evidence-shows-adalimumab-biosimilars-maintain-efficacy-despite-injection-site-tolerability-concerns 2025-12-04T06:13:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/real-world-evidence-shows-adalimumab-biosimilars-maintain-efficacy-despite-injection-site-tolerability-concerns 2025-12-04T06:13:33+00:00 hourly 0.9 https://trial.medpath.com/news/rentschler-biopharma-and-coriolis-pharma-form-strategic-alliance-to-deliver-integrated-biopharmaceutical-solutions 2025-12-04T06:11:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rentschler-biopharma-and-coriolis-pharma-form-strategic-alliance-to-deliver-integrated-biopharmaceutical-solutions 2025-12-04T06:11:49+00:00 hourly 0.9 https://trial.medpath.com/news/fda-clears-francis-medical-s-vanquish-water-vapor-system-for-intermediate-risk-prostate-cancer-treatment 2025-12-04T06:10:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-clears-francis-medical-s-vanquish-water-vapor-system-for-intermediate-risk-prostate-cancer-treatment 2025-12-04T06:10:24+00:00 hourly 0.9 https://trial.medpath.com/news/epcoritamab-demonstrates-strong-efficacy-in-elderly-dlbcl-and-follicular-lymphoma-patients-at-ash-2024 2025-12-04T06:10:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/epcoritamab-demonstrates-strong-efficacy-in-elderly-dlbcl-and-follicular-lymphoma-patients-at-ash-2024 2025-12-04T06:10:19+00:00 hourly 0.9 https://trial.medpath.com/news/medtronic-receives-fda-clearance-for-hugo-robotic-surgery-system-in-urology-procedures 2025-12-04T06:09:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/medtronic-receives-fda-clearance-for-hugo-robotic-surgery-system-in-urology-procedures 2025-12-04T06:09:41+00:00 hourly 0.9 https://trial.medpath.com/news/novo-nordisk-to-launch-ozempic-in-india-this-december-as-competition-intensifies-in-150-billion-weight-loss-market 2025-12-04T06:09:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novo-nordisk-to-launch-ozempic-in-india-this-december-as-competition-intensifies-in-150-billion-weight-loss-market 2025-12-04T06:09:05+00:00 hourly 0.9 https://trial.medpath.com/news/uk-clinical-trial-recruitment-drops-25-despite-government-reform-efforts 2025-12-04T06:08:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uk-clinical-trial-recruitment-drops-25-despite-government-reform-efforts 2025-12-04T06:08:39+00:00 hourly 0.9 https://trial.medpath.com/news/eli-lilly-commits-40-million-to-indiana-university-for-ai-enhanced-clinical-trial-infrastructure 2025-12-04T06:07:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eli-lilly-commits-40-million-to-indiana-university-for-ai-enhanced-clinical-trial-infrastructure 2025-12-04T06:07:21+00:00 hourly 0.9 https://trial.medpath.com/news/arrowhead-pharmaceuticals-receives-fda-breakthrough-therapy-designation-for-plozasiran-in-severe-hypertriglyceridemia 2025-12-04T06:06:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/arrowhead-pharmaceuticals-receives-fda-breakthrough-therapy-designation-for-plozasiran-in-severe-hypertriglyceridemia 2025-12-04T06:06:39+00:00 hourly 0.9 https://trial.medpath.com/news/fda-reduces-surveillance-requirements-for-seastar-medical-s-pediatric-aki-therapy-following-promising-safety-data 2025-12-04T06:04:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-reduces-surveillance-requirements-for-seastar-medical-s-pediatric-aki-therapy-following-promising-safety-data 2025-12-04T06:04:25+00:00 hourly 0.9 https://trial.medpath.com/news/novartis-advances-12-billion-acquisition-of-avidity-biosciences-for-rna-therapeutics-platform 2025-12-04T06:04:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novartis-advances-12-billion-acquisition-of-avidity-biosciences-for-rna-therapeutics-platform 2025-12-04T06:04:20+00:00 hourly 0.9 https://trial.medpath.com/news/inovio-pharmaceuticals-completes-bla-submission-for-first-in-class-dna-immunotherapy-ino-3107 2025-12-04T06:03:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/inovio-pharmaceuticals-completes-bla-submission-for-first-in-class-dna-immunotherapy-ino-3107 2025-12-04T06:03:59+00:00 hourly 0.9 https://trial.medpath.com/news/santen-and-singapore-eye-research-institute-launch-21-million-collaboration-to-develop-disease-modifying-eye-therapies 2025-12-04T06:02:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/santen-and-singapore-eye-research-institute-launch-21-million-collaboration-to-develop-disease-modifying-eye-therapies 2025-12-04T06:02:57+00:00 hourly 0.9 https://trial.medpath.com/news/virax-biolabs-advances-post-acute-infection-syndrome-diagnostics-with-completed-uk-trial-recruitment-and-fda-engagement 2025-12-04T06:02:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/virax-biolabs-advances-post-acute-infection-syndrome-diagnostics-with-completed-uk-trial-recruitment-and-fda-engagement 2025-12-04T06:02:55+00:00 hourly 0.9 https://trial.medpath.com/news/cardiol-therapeutics-cardiolrx-shows-significant-cardiac-benefits-in-phase-ii-myocarditis-trial 2025-12-04T06:02:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cardiol-therapeutics-cardiolrx-shows-significant-cardiac-benefits-in-phase-ii-myocarditis-trial 2025-12-04T06:02:10+00:00 hourly 0.9 https://trial.medpath.com/news/ltr-pharma-receives-ethics-approval-for-spontan-phase-2-trial-targeting-elderly-erectile-dysfunction-patients 2025-12-04T06:01:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ltr-pharma-receives-ethics-approval-for-spontan-phase-2-trial-targeting-elderly-erectile-dysfunction-patients 2025-12-04T06:01:56+00:00 hourly 0.9 https://trial.medpath.com/news/hoth-therapeutics-advances-multi-asset-pipeline-with-phase-2-progress-and-orphan-drug-designation 2025-12-04T06:00:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hoth-therapeutics-advances-multi-asset-pipeline-with-phase-2-progress-and-orphan-drug-designation 2025-12-04T06:00:58+00:00 hourly 0.9 https://trial.medpath.com/news/acumen-pharmaceuticals-demonstrates-68-fold-increase-in-brain-delivery-for-alzheimer-s-antibody-using-novel-transferrin-receptor-technology 2025-12-04T06:00:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/acumen-pharmaceuticals-demonstrates-68-fold-increase-in-brain-delivery-for-alzheimer-s-antibody-using-novel-transferrin-receptor-technology 2025-12-04T06:00:52+00:00 hourly 0.9 https://trial.medpath.com/news/renerva-receives-fda-approval-for-first-in-human-trial-of-novel-nerve-capping-device-to-prevent-chronic-amputation-pain 2025-12-04T05:59:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/renerva-receives-fda-approval-for-first-in-human-trial-of-novel-nerve-capping-device-to-prevent-chronic-amputation-pain 2025-12-04T05:59:08+00:00 hourly 0.9 https://trial.medpath.com/news/aethlon-medical-s-hemopurifier-shows-promise-for-long-covid-treatment-in-preclinical-study 2025-12-04T05:58:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aethlon-medical-s-hemopurifier-shows-promise-for-long-covid-treatment-in-preclinical-study 2025-12-04T05:58:50+00:00 hourly 0.9 https://trial.medpath.com/news/inmune-bio-advances-regulatory-pathways-for-cordstrom-and-xpro1595-programs 2025-12-04T05:58:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/inmune-bio-advances-regulatory-pathways-for-cordstrom-and-xpro1595-programs 2025-12-04T05:58:00+00:00 hourly 0.9 https://trial.medpath.com/news/granata-bio-advances-phase-iii-grace-study-for-investigational-gonadotropin-in-ivf-treatment 2025-12-04T05:57:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/granata-bio-advances-phase-iii-grace-study-for-investigational-gonadotropin-in-ivf-treatment 2025-12-04T05:57:57+00:00 hourly 0.9 https://trial.medpath.com/news/mezzion-secures-key-u-s-patent-for-udenafil-in-fontan-patients-extending-exclusivity-to-early-2040s 2025-12-04T05:57:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mezzion-secures-key-u-s-patent-for-udenafil-in-fontan-patients-extending-exclusivity-to-early-2040s 2025-12-04T05:57:43+00:00 hourly 0.9 https://trial.medpath.com/news/amplia-therapeutics-secures-u-s-patent-protection-for-fak-inhibitor-narmafotinib-through-2040 2025-12-04T05:56:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/amplia-therapeutics-secures-u-s-patent-protection-for-fak-inhibitor-narmafotinib-through-2040 2025-12-04T05:56:53+00:00 hourly 0.9 https://trial.medpath.com/news/rondo-therapeutics-initiates-first-in-human-trial-of-rndo-564-novel-bispecific-antibody-for-advanced-solid-tumors 2025-12-04T05:55:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rondo-therapeutics-initiates-first-in-human-trial-of-rndo-564-novel-bispecific-antibody-for-advanced-solid-tumors 2025-12-04T05:55:39+00:00 hourly 0.9 https://trial.medpath.com/news/archeus-technologies-initiates-first-in-human-trial-of-art-101-psma-targeting-radioligand-therapy-for-metastatic-prostate-cancer 2025-12-04T05:55:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/archeus-technologies-initiates-first-in-human-trial-of-art-101-psma-targeting-radioligand-therapy-for-metastatic-prostate-cancer 2025-12-04T05:55:33+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-expanded-approval-for-eli-lilly-s-jaypirca-in-earlier-line-cll-sll-treatment 2025-12-04T05:55:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-expanded-approval-for-eli-lilly-s-jaypirca-in-earlier-line-cll-sll-treatment 2025-12-04T05:55:30+00:00 hourly 0.9 https://trial.medpath.com/news/sutro-biopharma-initiates-phase-1-trial-of-stro-004-next-generation-tissue-factor-adc-for-advanced-solid-tumors 2025-12-04T05:55:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sutro-biopharma-initiates-phase-1-trial-of-stro-004-next-generation-tissue-factor-adc-for-advanced-solid-tumors 2025-12-04T05:55:27+00:00 hourly 0.9 https://trial.medpath.com/news/armr-sciences-initiates-first-human-trials-for-fentanyl-vaccine-in-early-2025 2025-12-04T05:54:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/armr-sciences-initiates-first-human-trials-for-fentanyl-vaccine-in-early-2025 2025-12-04T05:54:28+00:00 hourly 0.9 https://trial.medpath.com/news/polypid-receives-fda-support-for-d-plex100-nda-submission-following-positive-pre-nda-meeting 2025-12-04T05:54:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/polypid-receives-fda-support-for-d-plex100-nda-submission-following-positive-pre-nda-meeting 2025-12-04T05:54:25+00:00 hourly 0.9 https://trial.medpath.com/news/muvon-therapeutics-reports-breakthrough-phase-2-results-for-muscle-cell-based-stress-urinary-incontinence-therapy 2025-12-04T05:54:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/muvon-therapeutics-reports-breakthrough-phase-2-results-for-muscle-cell-based-stress-urinary-incontinence-therapy 2025-12-04T05:54:02+00:00 hourly 0.9 https://trial.medpath.com/news/hemophilia-gene-therapies-face-market-struggles-despite-scientific-promise 2025-12-04T05:53:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hemophilia-gene-therapies-face-market-struggles-despite-scientific-promise 2025-12-04T05:53:59+00:00 hourly 0.9 https://trial.medpath.com/news/pacira-s-cryoneurolysis-device-shows-superior-pain-relief-over-radiofrequency-ablation-in-chronic-low-back-pain-study 2025-12-04T05:53:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pacira-s-cryoneurolysis-device-shows-superior-pain-relief-over-radiofrequency-ablation-in-chronic-low-back-pain-study 2025-12-04T05:53:23+00:00 hourly 0.9 https://trial.medpath.com/news/ema-grants-conditional-marketing-authorization-for-immunitybio-s-anktiva-in-bladder-cancer 2025-12-04T05:53:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ema-grants-conditional-marketing-authorization-for-immunitybio-s-anktiva-in-bladder-cancer 2025-12-04T05:53:18+00:00 hourly 0.9 https://trial.medpath.com/news/natera-s-signatera-shows-superior-performance-in-lymphoma-detection-at-ash-2025 2025-12-04T05:52:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/natera-s-signatera-shows-superior-performance-in-lymphoma-detection-at-ash-2025 2025-12-04T05:52:34+00:00 hourly 0.9 https://trial.medpath.com/news/strm-bio-secures-8-4m-arpa-h-contract-to-develop-novel-extracellular-vesicle-platform-for-in-vivo-car-t-cell-engineering 2025-12-04T05:49:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/strm-bio-secures-8-4m-arpa-h-contract-to-develop-novel-extracellular-vesicle-platform-for-in-vivo-car-t-cell-engineering 2025-12-04T05:49:54+00:00 hourly 0.9 https://trial.medpath.com/news/onco3r-therapeutics-reports-positive-phase-1-data-for-novel-sik3-inhibitor-o3r-5671-in-autoimmune-disease-treatment 2025-12-04T05:49:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/onco3r-therapeutics-reports-positive-phase-1-data-for-novel-sik3-inhibitor-o3r-5671-in-autoimmune-disease-treatment 2025-12-04T05:49:39+00:00 hourly 0.9 https://trial.medpath.com/news/taiwan-approves-nt-100-million-gene-therapy-for-rare-aadc-deficiency-amid-coverage-debate 2025-12-04T05:49:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/taiwan-approves-nt-100-million-gene-therapy-for-rare-aadc-deficiency-amid-coverage-debate 2025-12-04T05:49:36+00:00 hourly 0.9 https://trial.medpath.com/news/belite-bio-s-tinlarebant-achieves-35-7-reduction-in-lesion-growth-in-first-successful-phase-3-trial-for-stargardt-disease 2025-12-04T05:44:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/belite-bio-s-tinlarebant-achieves-35-7-reduction-in-lesion-growth-in-first-successful-phase-3-trial-for-stargardt-disease 2025-12-04T05:44:20+00:00 hourly 0.9 https://trial.medpath.com/news/university-of-virginia-launches-clinical-trial-for-new-covid-19-treatment-targeting-outpatients 2025-12-04T05:44:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/university-of-virginia-launches-clinical-trial-for-new-covid-19-treatment-targeting-outpatients 2025-12-04T05:44:12+00:00 hourly 0.9 https://trial.medpath.com/news/australia-issues-new-safety-warnings-for-glp-1-drugs-following-reports-of-suicidal-thoughts 2025-12-04T05:44:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/australia-issues-new-safety-warnings-for-glp-1-drugs-following-reports-of-suicidal-thoughts 2025-12-04T05:44:04+00:00 hourly 0.9 https://trial.medpath.com/news/bausch-lomb-partners-with-ripple-therapeutics-to-develop-polymer-free-sustained-release-ophthalmic-implants 2025-12-04T05:43:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bausch-lomb-partners-with-ripple-therapeutics-to-develop-polymer-free-sustained-release-ophthalmic-implants 2025-12-04T05:43:48+00:00 hourly 0.9 https://trial.medpath.com/news/jasper-therapeutics-reports-positive-phase-1b-data-for-briquilimab-in-asthma-completes-beacon-study-investigation 2025-12-04T05:43:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/jasper-therapeutics-reports-positive-phase-1b-data-for-briquilimab-in-asthma-completes-beacon-study-investigation 2025-12-04T05:43:00+00:00 hourly 0.9 https://trial.medpath.com/news/roche-receives-fda-clearance-for-15-minute-point-of-care-bordetella-pcr-test 2025-12-04T05:42:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/roche-receives-fda-clearance-for-15-minute-point-of-care-bordetella-pcr-test 2025-12-04T05:42:54+00:00 hourly 0.9 https://trial.medpath.com/news/two-companies-launch-competing-glp-1-clinical-trials-for-feline-weight-management 2025-12-04T05:41:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/two-companies-launch-competing-glp-1-clinical-trials-for-feline-weight-management 2025-12-04T05:41:37+00:00 hourly 0.9 https://trial.medpath.com/news/akiram-therapeutics-advances-cd44v6-targeted-radiotherapy-akir001-with-cohort-2b-clearance-and-journal-publication 2025-12-04T05:40:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/akiram-therapeutics-advances-cd44v6-targeted-radiotherapy-akir001-with-cohort-2b-clearance-and-journal-publication 2025-12-04T05:40:58+00:00 hourly 0.9 https://trial.medpath.com/news/fda-issues-alert-after-seven-deaths-linked-to-abbott-freestyle-libre-3-glucose-monitor-defects 2025-12-04T05:39:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-issues-alert-after-seven-deaths-linked-to-abbott-freestyle-libre-3-glucose-monitor-defects 2025-12-04T05:39:46+00:00 hourly 0.9 https://trial.medpath.com/news/glp-1-pricing-agreements-open-market-for-new-obesity-drug-competitors 2025-12-04T05:37:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/glp-1-pricing-agreements-open-market-for-new-obesity-drug-competitors 2025-12-04T05:37:56+00:00 hourly 0.9 https://trial.medpath.com/news/lotus-pharma-submits-first-regulatory-application-for-vizz-presbyopia-treatment-in-south-korea 2025-12-04T05:37:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lotus-pharma-submits-first-regulatory-application-for-vizz-presbyopia-treatment-in-south-korea 2025-12-04T05:37:54+00:00 hourly 0.9 https://trial.medpath.com/news/4d-path-s-ai-platform-predicts-chemotherapy-response-in-triple-negative-breast-cancer-using-standard-biopsy-images 2025-12-04T05:37:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/4d-path-s-ai-platform-predicts-chemotherapy-response-in-triple-negative-breast-cancer-using-standard-biopsy-images 2025-12-04T05:37:51+00:00 hourly 0.9 https://trial.medpath.com/news/outlook-therapeutics-awaits-critical-fda-decision-on-first-ophthalmic-bevacizumab-for-wet-amd-by-december-31 2025-12-04T05:37:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/outlook-therapeutics-awaits-critical-fda-decision-on-first-ophthalmic-bevacizumab-for-wet-amd-by-december-31 2025-12-04T05:37:15+00:00 hourly 0.9 https://trial.medpath.com/news/automated-lung-organoid-production-breakthrough-promises-to-accelerate-respiratory-drug-development 2025-12-04T05:37:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/automated-lung-organoid-production-breakthrough-promises-to-accelerate-respiratory-drug-development 2025-12-04T05:37:13+00:00 hourly 0.9 https://trial.medpath.com/news/pentixapharm-receives-fda-guidance-for-phase-3-panda-study-of-68ga-pentixafor-in-primary-aldosteronism 2025-12-04T05:37:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pentixapharm-receives-fda-guidance-for-phase-3-panda-study-of-68ga-pentixafor-in-primary-aldosteronism 2025-12-04T05:37:10+00:00 hourly 0.9 https://trial.medpath.com/news/excelsior-sciences-secures-95-million-to-revolutionize-ai-driven-small-molecule-drug-discovery 2025-12-04T05:37:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/excelsior-sciences-secures-95-million-to-revolutionize-ai-driven-small-molecule-drug-discovery 2025-12-04T05:37:07+00:00 hourly 0.9 https://trial.medpath.com/news/quadriga-biosciences-reports-promising-phase-iia-results-for-qbs72s-in-breast-cancer-leptomeningeal-disease 2025-12-04T05:37:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/quadriga-biosciences-reports-promising-phase-iia-results-for-qbs72s-in-breast-cancer-leptomeningeal-disease 2025-12-04T05:37:01+00:00 hourly 0.9 https://trial.medpath.com/news/protara-s-tara-002-shows-72-complete-response-rate-in-bcg-naive-bladder-cancer-patients 2025-12-04T05:36:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/protara-s-tara-002-shows-72-complete-response-rate-in-bcg-naive-bladder-cancer-patients 2025-12-04T05:36:55+00:00 hourly 0.9 https://trial.medpath.com/news/relmada-therapeutics-presents-promising-6-month-data-for-ndv-01-bladder-cancer-treatment-at-urologic-oncology-meeting 2025-12-04T05:36:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/relmada-therapeutics-presents-promising-6-month-data-for-ndv-01-bladder-cancer-treatment-at-urologic-oncology-meeting 2025-12-04T05:36:52+00:00 hourly 0.9 https://trial.medpath.com/news/illumina-and-myome-partner-to-advance-200-billion-healthcare-savings-through-ai-driven-genomic-medicine 2025-12-04T05:36:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/illumina-and-myome-partner-to-advance-200-billion-healthcare-savings-through-ai-driven-genomic-medicine 2025-12-04T05:36:50+00:00 hourly 0.9 https://trial.medpath.com/news/who-approves-olastrocel-as-international-name-for-creative-medical-s-lead-cell-therapy-celz-201 2025-12-04T05:35:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/who-approves-olastrocel-as-international-name-for-creative-medical-s-lead-cell-therapy-celz-201 2025-12-04T05:35:19+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-accelerated-approval-to-otsuka-s-voyxact-for-iga-nephropathy-first-april-targeting-therapy 2025-12-04T05:35:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-accelerated-approval-to-otsuka-s-voyxact-for-iga-nephropathy-first-april-targeting-therapy 2025-12-04T05:35:09+00:00 hourly 0.9 https://trial.medpath.com/news/cms-approves-47-payment-increase-for-optical-genome-mapping-in-blood-cancer-diagnostics 2025-12-04T05:35:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cms-approves-47-payment-increase-for-optical-genome-mapping-in-blood-cancer-diagnostics 2025-12-04T05:35:07+00:00 hourly 0.9 https://trial.medpath.com/news/two-novel-alzheimer-s-therapies-advance-in-phase-2-trials-oral-pri-002-and-trem2-targeting-vhb937 2025-12-04T05:33:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/two-novel-alzheimer-s-therapies-advance-in-phase-2-trials-oral-pri-002-and-trem2-targeting-vhb937 2025-12-04T05:33:58+00:00 hourly 0.9 https://trial.medpath.com/news/federal-appeals-court-overturns-41-million-patent-verdict-against-daiichi-sankyo-s-enhertu-adc 2025-12-04T05:33:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/federal-appeals-court-overturns-41-million-patent-verdict-against-daiichi-sankyo-s-enhertu-adc 2025-12-04T05:33:09+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-300mg-strength-of-celltrion-s-omlyclo-first-interchangeable-biosimilar-to-xolair 2025-12-04T05:33:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-300mg-strength-of-celltrion-s-omlyclo-first-interchangeable-biosimilar-to-xolair 2025-12-04T05:33:03+00:00 hourly 0.9 https://trial.medpath.com/news/jaguar-health-seeks-ema-approval-for-canalevia-in-european-union-to-treat-general-diarrhea-in-dogs 2025-12-04T05:32:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/jaguar-health-seeks-ema-approval-for-canalevia-in-european-union-to-treat-general-diarrhea-in-dogs 2025-12-04T05:32:58+00:00 hourly 0.9 https://trial.medpath.com/news/samsung-bioepis-secures-european-approval-for-byooviz-pre-filled-syringe-formulation 2025-12-04T05:32:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/samsung-bioepis-secures-european-approval-for-byooviz-pre-filled-syringe-formulation 2025-12-04T05:32:55+00:00 hourly 0.9 https://trial.medpath.com/news/ensysce-biosciences-secures-extended-patent-protection-for-mpar-overdose-prevention-technology-through-2042 2025-12-04T05:32:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ensysce-biosciences-secures-extended-patent-protection-for-mpar-overdose-prevention-technology-through-2042 2025-12-04T05:32:52+00:00 hourly 0.9 https://trial.medpath.com/news/strand-therapeutics-appoints-former-nimbus-ceo-jeb-keiper-to-board-as-company-advances-programmable-mrna-platform 2025-12-04T05:32:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/strand-therapeutics-appoints-former-nimbus-ceo-jeb-keiper-to-board-as-company-advances-programmable-mrna-platform 2025-12-04T05:32:46+00:00 hourly 0.9 https://trial.medpath.com/news/china-s-pharmaceutical-patent-linkage-system-shows-growing-judicial-maturity-after-four-years-of-operation 2025-12-04T05:32:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/china-s-pharmaceutical-patent-linkage-system-shows-growing-judicial-maturity-after-four-years-of-operation 2025-12-04T05:32:06+00:00 hourly 0.9 https://trial.medpath.com/news/fda-clears-first-in-class-vectorized-antibody-trial-for-als-targeting-tdp-43-pathology 2025-12-04T05:31:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-clears-first-in-class-vectorized-antibody-trial-for-als-targeting-tdp-43-pathology 2025-12-04T05:31:51+00:00 hourly 0.9 https://trial.medpath.com/news/jupiter-neurosciences-advances-jotrol-into-phase-2a-parkinson-s-trial-following-fda-clearance 2025-12-04T05:31:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/jupiter-neurosciences-advances-jotrol-into-phase-2a-parkinson-s-trial-following-fda-clearance 2025-12-04T05:31:48+00:00 hourly 0.9 https://trial.medpath.com/news/leqembi-shows-measurable-target-engagement-with-alzheimer-s-protofibrils-in-cerebrospinal-fluid 2025-12-04T05:31:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/leqembi-shows-measurable-target-engagement-with-alzheimer-s-protofibrils-in-cerebrospinal-fluid 2025-12-04T05:31:45+00:00 hourly 0.9 https://trial.medpath.com/news/moderna-faces-regulatory-headwinds-as-fda-signals-stricter-vaccine-approval-standards 2025-12-04T05:31:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/moderna-faces-regulatory-headwinds-as-fda-signals-stricter-vaccine-approval-standards 2025-12-04T05:31:43+00:00 hourly 0.9 https://trial.medpath.com/news/nrx-pharmaceuticals-expands-nrx-101-development-to-include-combination-therapy-with-transcranial-magnetic-stimulation-for-depression 2025-12-04T05:31:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nrx-pharmaceuticals-expands-nrx-101-development-to-include-combination-therapy-with-transcranial-magnetic-stimulation-for-depression 2025-12-04T05:31:40+00:00 hourly 0.9 https://trial.medpath.com/news/cosmo-s-clascoterone-5-topical-solution-achieves-breakthrough-results-in-phase-iii-male-pattern-hair-loss-trials 2025-12-04T05:31:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cosmo-s-clascoterone-5-topical-solution-achieves-breakthrough-results-in-phase-iii-male-pattern-hair-loss-trials 2025-12-04T05:31:34+00:00 hourly 0.9 https://trial.medpath.com/news/avecho-biotechnology-secures-us-and-eu-patent-protection-for-cbd-insomnia-treatment-through-2040 2025-12-04T05:31:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/avecho-biotechnology-secures-us-and-eu-patent-protection-for-cbd-insomnia-treatment-through-2040 2025-12-04T05:31:22+00:00 hourly 0.9 https://trial.medpath.com/news/aob-pharma-secures-ema-pediatric-investigation-plan-approval-for-b244-atopic-dermatitis-treatment-with-topical-corticosteroid-waiver 2025-12-04T05:30:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aob-pharma-secures-ema-pediatric-investigation-plan-approval-for-b244-atopic-dermatitis-treatment-with-topical-corticosteroid-waiver 2025-12-04T05:30:30+00:00 hourly 0.9 https://trial.medpath.com/news/triana-biomedicines-secures-120m-series-b-to-advance-alk-targeted-molecular-glue-degrader-for-lung-cancer 2025-12-04T05:29:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/triana-biomedicines-secures-120m-series-b-to-advance-alk-targeted-molecular-glue-degrader-for-lung-cancer 2025-12-04T05:29:53+00:00 hourly 0.9 https://trial.medpath.com/news/paradigm-trial-shows-venetoclax-azacitidine-superior-to-intensive-chemotherapy-in-newly-diagnosed-aml 2025-12-04T05:29:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/paradigm-trial-shows-venetoclax-azacitidine-superior-to-intensive-chemotherapy-in-newly-diagnosed-aml 2025-12-04T05:29:47+00:00 hourly 0.9 https://trial.medpath.com/news/citizen-health-and-ucb-launch-strategic-partnership-to-accelerate-epilepsy-and-rare-disease-drug-development-using-ai 2025-12-04T05:29:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/citizen-health-and-ucb-launch-strategic-partnership-to-accelerate-epilepsy-and-rare-disease-drug-development-using-ai 2025-12-04T05:29:37+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-enfortumab-vedotin-plus-pembrolizumab-for-perioperative-treatment-of-muscle-invasive-bladder-cancer 2025-12-04T05:29:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-enfortumab-vedotin-plus-pembrolizumab-for-perioperative-treatment-of-muscle-invasive-bladder-cancer 2025-12-04T05:29:35+00:00 hourly 0.9 https://trial.medpath.com/news/greenwich-lifesciences-completes-enrollment-in-non-hla-a-02-arm-of-phase-iii-flamingo-01-trial-for-breast-cancer-prevention 2025-12-04T05:28:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/greenwich-lifesciences-completes-enrollment-in-non-hla-a-02-arm-of-phase-iii-flamingo-01-trial-for-breast-cancer-prevention 2025-12-04T05:28:57+00:00 hourly 0.9 https://trial.medpath.com/news/abemaciclib-monotherapy-shows-promise-after-cdk4-6-inhibitor-failure-in-hr-her2-breast-cancer 2025-12-04T05:28:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/abemaciclib-monotherapy-shows-promise-after-cdk4-6-inhibitor-failure-in-hr-her2-breast-cancer 2025-12-04T05:28:22+00:00 hourly 0.9 https://trial.medpath.com/news/alkeus-pharmaceuticals-appoints-carlos-quezada-ruiz-as-chief-medical-officer-to-lead-stargardt-disease-drug-development 2025-12-04T05:28:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alkeus-pharmaceuticals-appoints-carlos-quezada-ruiz-as-chief-medical-officer-to-lead-stargardt-disease-drug-development 2025-12-04T05:28:19+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-amneal-s-generic-cyclosporine-eye-drops-for-dry-eye-disease-treatment 2025-12-04T05:28:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-amneal-s-generic-cyclosporine-eye-drops-for-dry-eye-disease-treatment 2025-12-04T05:28:16+00:00 hourly 0.9 https://trial.medpath.com/news/biofrontera-submits-fda-application-for-ameluz-pdt-in-superficial-basal-cell-carcinoma-treatment 2025-12-04T05:28:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biofrontera-submits-fda-application-for-ameluz-pdt-in-superficial-basal-cell-carcinoma-treatment 2025-12-04T05:28:11+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-daratumumab-for-high-risk-smoldering-multiple-myeloma-following-landmark-aquila-trial-results 2025-12-04T05:28:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-daratumumab-for-high-risk-smoldering-multiple-myeloma-following-landmark-aquila-trial-results 2025-12-04T05:28:00+00:00 hourly 0.9 https://trial.medpath.com/news/zynlonta-plus-glofitamab-achieves-89-8-response-rate-in-relapsed-refractory-dlbcl-trial 2025-12-04T05:27:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/zynlonta-plus-glofitamab-achieves-89-8-response-rate-in-relapsed-refractory-dlbcl-trial 2025-12-04T05:27:57+00:00 hourly 0.9 https://trial.medpath.com/news/alzecure-receives-eur2-5-million-eu-grant-to-advance-phase-2a-trial-of-novel-alzheimer-s-drug-acd856 2025-12-04T05:27:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alzecure-receives-eur2-5-million-eu-grant-to-advance-phase-2a-trial-of-novel-alzheimer-s-drug-acd856 2025-12-04T05:27:51+00:00 hourly 0.9 https://trial.medpath.com/news/harmony-biosciences-to-present-phase-3-epx-100-data-for-dravet-syndrome-at-aes-annual-meeting 2025-12-04T05:27:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/harmony-biosciences-to-present-phase-3-epx-100-data-for-dravet-syndrome-at-aes-annual-meeting 2025-12-04T05:27:33+00:00 hourly 0.9 https://trial.medpath.com/news/elevar-s-rivoceranib-camrelizumab-combination-shows-significant-survival-benefit-in-phase-3-liver-cancer-trial 2025-12-04T05:27:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/elevar-s-rivoceranib-camrelizumab-combination-shows-significant-survival-benefit-in-phase-3-liver-cancer-trial 2025-12-04T05:27:30+00:00 hourly 0.9 https://trial.medpath.com/news/savara-secures-european-patent-protection-for-molbreevi-through-2041-strengthening-ip-portfolio-for-rare-lung-disease-therapy 2025-12-04T05:27:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/savara-secures-european-patent-protection-for-molbreevi-through-2041-strengthening-ip-portfolio-for-rare-lung-disease-therapy 2025-12-04T05:27:24+00:00 hourly 0.9 https://trial.medpath.com/news/sagent-pharmaceuticals-partners-with-provepharm-to-launch-bludigo-first-fda-approved-injectable-indigo-carmine-diagnostic-dye 2025-12-04T05:26:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sagent-pharmaceuticals-partners-with-provepharm-to-launch-bludigo-first-fda-approved-injectable-indigo-carmine-diagnostic-dye 2025-12-04T05:26:47+00:00 hourly 0.9 https://trial.medpath.com/news/kura-oncology-receives-135-million-milestone-payment-as-komzifti-achieves-first-commercial-sale 2025-12-04T05:26:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kura-oncology-receives-135-million-milestone-payment-as-komzifti-achieves-first-commercial-sale 2025-12-04T05:26:41+00:00 hourly 0.9 https://trial.medpath.com/news/pharvaris-reports-positive-phase-3-results-for-oral-hae-treatment-deucrictibant 2025-12-04T05:26:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pharvaris-reports-positive-phase-3-results-for-oral-hae-treatment-deucrictibant 2025-12-04T05:26:27+00:00 hourly 0.9 https://trial.medpath.com/news/latus-bio-receives-fda-ind-clearance-for-lts-101-gene-therapy-to-treat-fatal-cln2-disease-in-children 2025-12-04T05:26:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/latus-bio-receives-fda-ind-clearance-for-lts-101-gene-therapy-to-treat-fatal-cln2-disease-in-children 2025-12-04T05:26:24+00:00 hourly 0.9 https://trial.medpath.com/news/immuron-secures-us-department-of-defense-award-for-novel-oral-therapeutics-against-military-priority-pathogens 2025-12-04T05:26:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/immuron-secures-us-department-of-defense-award-for-novel-oral-therapeutics-against-military-priority-pathogens 2025-12-04T05:26:18+00:00 hourly 0.9 https://trial.medpath.com/news/pedmark-shows-significant-reduction-in-cisplatin-induced-hearing-loss-in-japanese-pediatric-cancer-study 2025-12-04T05:26:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pedmark-shows-significant-reduction-in-cisplatin-induced-hearing-loss-in-japanese-pediatric-cancer-study 2025-12-04T05:26:15+00:00 hourly 0.9 https://trial.medpath.com/news/incannex-healthcare-receives-fda-fast-track-designation-for-ihl-42x-in-obstructive-sleep-apnea 2025-12-04T05:24:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/incannex-healthcare-receives-fda-fast-track-designation-for-ihl-42x-in-obstructive-sleep-apnea 2025-12-04T05:24:25+00:00 hourly 0.9 https://trial.medpath.com/news/iolyx-therapeutics-secures-280m-partnership-with-laboratoires-thea-for-autoimmune-dry-eye-treatment 2025-12-04T05:24:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/iolyx-therapeutics-secures-280m-partnership-with-laboratoires-thea-for-autoimmune-dry-eye-treatment 2025-12-04T05:24:22+00:00 hourly 0.9 https://trial.medpath.com/news/amneal-secures-fda-approval-for-generic-albuterol-inhaler-marking-second-respiratory-win-in-q4-2025 2025-12-04T05:24:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/amneal-secures-fda-approval-for-generic-albuterol-inhaler-marking-second-respiratory-win-in-q4-2025 2025-12-04T05:24:00+00:00 hourly 0.9 https://trial.medpath.com/news/silexion-therapeutics-receives-german-regulatory-approval-for-phase-2-3-pancreatic-cancer-trial-design 2025-12-04T05:23:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/silexion-therapeutics-receives-german-regulatory-approval-for-phase-2-3-pancreatic-cancer-trial-design 2025-12-04T05:23:57+00:00 hourly 0.9 https://trial.medpath.com/news/abbvie-presents-breakthrough-data-at-ash-2025-demonstrating-significant-advances-in-blood-cancer-treatment 2025-12-04T05:23:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/abbvie-presents-breakthrough-data-at-ash-2025-demonstrating-significant-advances-in-blood-cancer-treatment 2025-12-04T05:23:49+00:00 hourly 0.9 https://trial.medpath.com/news/black-diamond-therapeutics-to-present-phase-2-silevertinib-results-for-egfr-mutant-nsclc 2025-12-04T05:23:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/black-diamond-therapeutics-to-present-phase-2-silevertinib-results-for-egfr-mutant-nsclc 2025-12-04T05:23:46+00:00 hourly 0.9 https://trial.medpath.com/news/delhi-high-court-allows-dr-reddy-s-to-export-semaglutide-challenges-novo-nordisk-patent-validity 2025-12-04T05:23:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/delhi-high-court-allows-dr-reddy-s-to-export-semaglutide-challenges-novo-nordisk-patent-validity 2025-12-04T05:23:14+00:00 hourly 0.9 https://trial.medpath.com/news/tiakis-biotech-advances-tiprelestat-to-phase-ii-trial-for-pulmonary-arterial-hypertension-following-positive-safety-data 2025-12-04T05:23:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tiakis-biotech-advances-tiprelestat-to-phase-ii-trial-for-pulmonary-arterial-hypertension-following-positive-safety-data 2025-12-04T05:23:09+00:00 hourly 0.9 https://trial.medpath.com/news/quetzal-therapeutics-initiates-phase-iii-trial-of-oral-arsenic-trioxide-qtx-2101-for-acute-promyelocytic-leukemia 2025-12-04T05:23:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/quetzal-therapeutics-initiates-phase-iii-trial-of-oral-arsenic-trioxide-qtx-2101-for-acute-promyelocytic-leukemia 2025-12-04T05:23:06+00:00 hourly 0.9 https://trial.medpath.com/news/uk-approves-tisotumab-vedotin-for-recurrent-cervical-cancer-demonstrating-30-reduction-in-death-risk 2025-12-04T05:23:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uk-approves-tisotumab-vedotin-for-recurrent-cervical-cancer-demonstrating-30-reduction-in-death-risk 2025-12-04T05:23:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-wave-of-oncology-drugs-and-biosimilars-in-november-2025-expanding-treatment-access 2025-12-04T05:22:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-wave-of-oncology-drugs-and-biosimilars-in-november-2025-expanding-treatment-access 2025-12-04T05:22:57+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-ziftomenib-first-in-class-targeted-therapy-for-npm1-mutated-acute-myeloid-leukemia 2025-12-04T05:22:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-ziftomenib-first-in-class-targeted-therapy-for-npm1-mutated-acute-myeloid-leukemia 2025-12-04T05:22:22+00:00 hourly 0.9 https://trial.medpath.com/news/bristol-myers-squibb-delays-cobenfy-alzheimer-s-psychosis-trial-results-to-2026-following-site-irregularities 2025-12-04T05:21:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bristol-myers-squibb-delays-cobenfy-alzheimer-s-psychosis-trial-results-to-2026-following-site-irregularities 2025-12-04T05:21:28+00:00 hourly 0.9 https://trial.medpath.com/news/vandria-s-vna-318-shows-promising-phase-1-results-with-novel-dual-action-mechanism-for-alzheimer-s-disease 2025-12-04T05:21:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vandria-s-vna-318-shows-promising-phase-1-results-with-novel-dual-action-mechanism-for-alzheimer-s-disease 2025-12-04T05:21:22+00:00 hourly 0.9 https://trial.medpath.com/news/polaritybio-completes-phase-iii-trial-of-skinte-for-diabetic-foot-ulcers-targets-first-bla-approval-since-1997 2025-12-04T05:21:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/polaritybio-completes-phase-iii-trial-of-skinte-for-diabetic-foot-ulcers-targets-first-bla-approval-since-1997 2025-12-04T05:21:19+00:00 hourly 0.9 https://trial.medpath.com/news/ai-powered-remote-monitoring-shows-promise-for-reducing-patient-burden-in-clinical-trials 2025-12-04T05:21:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ai-powered-remote-monitoring-shows-promise-for-reducing-patient-burden-in-clinical-trials 2025-12-04T05:21:16+00:00 hourly 0.9 https://trial.medpath.com/news/roche-s-trontinemab-shows-92-amyloid-clearance-success-in-alzheimer-s-mid-stage-trial 2025-12-04T05:21:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/roche-s-trontinemab-shows-92-amyloid-clearance-success-in-alzheimer-s-mid-stage-trial 2025-12-04T05:21:14+00:00 hourly 0.9 https://trial.medpath.com/news/fda-chief-claims-covid-19-vaccines-linked-to-10-pediatric-deaths-sparking-expert-criticism-and-market-decline 2025-12-04T05:21:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-chief-claims-covid-19-vaccines-linked-to-10-pediatric-deaths-sparking-expert-criticism-and-market-decline 2025-12-04T05:21:00+00:00 hourly 0.9 https://trial.medpath.com/news/us-house-passes-bipartisan-bill-to-reauthorize-fda-s-rare-pediatric-disease-priority-review-voucher-program 2025-12-04T05:20:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/us-house-passes-bipartisan-bill-to-reauthorize-fda-s-rare-pediatric-disease-priority-review-voucher-program 2025-12-04T05:20:58+00:00 hourly 0.9 https://trial.medpath.com/news/roche-s-trontinemab-shows-92-success-rate-in-clearing-alzheimer-s-amyloid-plaques 2025-12-04T05:20:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/roche-s-trontinemab-shows-92-success-rate-in-clearing-alzheimer-s-amyloid-plaques 2025-12-04T05:20:49+00:00 hourly 0.9 https://trial.medpath.com/news/fda-deploys-agentic-ai-across-agency-to-accelerate-drug-reviews-and-modernize-regulatory-workflows 2025-12-04T05:20:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-deploys-agentic-ai-across-agency-to-accelerate-drug-reviews-and-modernize-regulatory-workflows 2025-12-04T05:20:47+00:00 hourly 0.9 https://trial.medpath.com/news/bayer-proposes-7-25-billion-roundup-settlement-as-trump-administration-backs-supreme-court-appeal 2025-12-03T22:41:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bayer-proposes-7-25-billion-roundup-settlement-as-trump-administration-backs-supreme-court-appeal 2025-12-03T22:41:00+00:00 hourly 0.9 https://trial.medpath.com/news/medicus-pharma-appoints-carolyn-bonner-as-cfo-while-advancing-multiple-clinical-programs 2025-12-03T15:22:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/medicus-pharma-appoints-carolyn-bonner-as-cfo-while-advancing-multiple-clinical-programs 2025-12-03T15:22:00+00:00 hourly 0.9 https://trial.medpath.com/news/phase-i-trial-evaluates-pevonedistat-capecitabine-oxaliplatin-combination-for-advanced-gastric-cancer 2025-12-03T08:23:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/phase-i-trial-evaluates-pevonedistat-capecitabine-oxaliplatin-combination-for-advanced-gastric-cancer 2025-12-03T08:23:38+00:00 hourly 0.9 https://trial.medpath.com/news/imvax-plans-fda-discussions-for-glioblastoma-therapy-despite-missing-primary-endpoint 2025-12-03T06:27:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/imvax-plans-fda-discussions-for-glioblastoma-therapy-despite-missing-primary-endpoint 2025-12-03T06:27:05+00:00 hourly 0.9 https://trial.medpath.com/news/ai-driven-study-identifies-z-endoxifen-as-promising-therapeutic-candidate-for-glioblastoma 2025-12-03T06:25:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ai-driven-study-identifies-z-endoxifen-as-promising-therapeutic-candidate-for-glioblastoma 2025-12-03T06:25:49+00:00 hourly 0.9 https://trial.medpath.com/news/curi-bio-raises-10m-series-b-to-scale-human-ipsc-platforms-for-drug-discovery 2025-12-03T06:25:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/curi-bio-raises-10m-series-b-to-scale-human-ipsc-platforms-for-drug-discovery 2025-12-03T06:25:43+00:00 hourly 0.9 https://trial.medpath.com/news/diagnostear-partners-with-alyatec-for-clinical-validation-of-revolutionary-red-eye-diagnostic-test 2025-12-03T06:25:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/diagnostear-partners-with-alyatec-for-clinical-validation-of-revolutionary-red-eye-diagnostic-test 2025-12-03T06:25:32+00:00 hourly 0.9 https://trial.medpath.com/news/amgen-secures-fda-approval-for-imdelltra-in-small-cell-lung-cancer-as-pipeline-advances-drive-growth 2025-12-03T06:25:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/amgen-secures-fda-approval-for-imdelltra-in-small-cell-lung-cancer-as-pipeline-advances-drive-growth 2025-12-03T06:25:15+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-orphan-drug-designation-to-birchbiomed-s-fs2-for-idiopathic-pulmonary-fibrosis-treatment 2025-12-03T06:25:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-orphan-drug-designation-to-birchbiomed-s-fs2-for-idiopathic-pulmonary-fibrosis-treatment 2025-12-03T06:25:12+00:00 hourly 0.9 https://trial.medpath.com/news/engene-s-detalimogene-selected-for-fda-manufacturing-pilot-program-to-accelerate-bladder-cancer-gene-therapy-development 2025-12-03T06:25:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/engene-s-detalimogene-selected-for-fda-manufacturing-pilot-program-to-accelerate-bladder-cancer-gene-therapy-development 2025-12-03T06:25:06+00:00 hourly 0.9 https://trial.medpath.com/news/uk-secures-zero-tariff-us-pharmaceutical-deal-with-25-increase-in-nhs-medicine-investment 2025-12-03T06:25:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uk-secures-zero-tariff-us-pharmaceutical-deal-with-25-increase-in-nhs-medicine-investment 2025-12-03T06:25:01+00:00 hourly 0.9 https://trial.medpath.com/news/electra-therapeutics-advances-ela026-in-pivotal-trial-for-rare-blood-disorder-shlh 2025-12-03T06:24:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/electra-therapeutics-advances-ela026-in-pivotal-trial-for-rare-blood-disorder-shlh 2025-12-03T06:24:49+00:00 hourly 0.9 https://trial.medpath.com/news/fda-issues-draft-guidance-to-reduce-primate-testing-for-monoclonal-antibody-therapies 2025-12-03T06:24:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-issues-draft-guidance-to-reduce-primate-testing-for-monoclonal-antibody-therapies 2025-12-03T06:24:44+00:00 hourly 0.9 https://trial.medpath.com/news/antengene-receives-nmpa-approval-for-phase-ib-ii-study-of-atg-022-cldn18-2-adc-in-combination-with-pembrolizumab-for-gastric-cancer 2025-12-03T06:23:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/antengene-receives-nmpa-approval-for-phase-ib-ii-study-of-atg-022-cldn18-2-adc-in-combination-with-pembrolizumab-for-gastric-cancer 2025-12-03T06:23:57+00:00 hourly 0.9 https://trial.medpath.com/news/ajovy-becomes-first-cgrp-antagonist-approved-for-pediatric-migraine-prevention-following-positive-space-trial-results 2025-12-03T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ajovy-becomes-first-cgrp-antagonist-approved-for-pediatric-migraine-prevention-following-positive-space-trial-results 2025-12-03T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/tang-capital-management-invests-56-8-million-in-celcuity-following-positive-phase-3-gedatolisib-results 2025-12-02T22:41:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tang-capital-management-invests-56-8-million-in-celcuity-following-positive-phase-3-gedatolisib-results 2025-12-02T22:41:00+00:00 hourly 0.9 https://trial.medpath.com/news/mirum-pharmaceuticals-initiates-phase-ii-trial-of-mrm-3379-for-fragile-x-syndrome 2025-12-02T15:15:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mirum-pharmaceuticals-initiates-phase-ii-trial-of-mrm-3379-for-fragile-x-syndrome 2025-12-02T15:15:00+00:00 hourly 0.9 https://trial.medpath.com/news/breast-cancer-index-test-shows-promise-for-identifying-low-risk-premenopausal-patients-who-may-avoid-aggressive-therapy 2025-12-02T13:32:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/breast-cancer-index-test-shows-promise-for-identifying-low-risk-premenopausal-patients-who-may-avoid-aggressive-therapy 2025-12-02T13:32:00+00:00 hourly 0.9 https://trial.medpath.com/news/bionexus-gene-lab-launches-vitaguard-mrd-platform-across-southeast-asia-to-challenge-3000-legacy-cancer-monitoring-systems 2025-12-02T13:06:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bionexus-gene-lab-launches-vitaguard-mrd-platform-across-southeast-asia-to-challenge-3000-legacy-cancer-monitoring-systems 2025-12-02T13:06:00+00:00 hourly 0.9 https://trial.medpath.com/news/3d-printed-corneal-implant-restores-sight-to-legally-blind-patient-in-world-first-surgery 2025-12-02T12:07:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/3d-printed-corneal-implant-restores-sight-to-legally-blind-patient-in-world-first-surgery 2025-12-02T12:07:00+00:00 hourly 0.9 https://trial.medpath.com/news/neurothera-labs-pursues-quantum-computing-acquisition-to-accelerate-cns-drug-development 2025-12-02T09:30:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/neurothera-labs-pursues-quantum-computing-acquisition-to-accelerate-cns-drug-development 2025-12-02T09:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/nice-approves-papillon-brachytherapy-for-nhs-use-in-early-stage-rectal-cancer 2025-12-02T05:26:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nice-approves-papillon-brachytherapy-for-nhs-use-in-early-stage-rectal-cancer 2025-12-02T05:26:40+00:00 hourly 0.9 https://trial.medpath.com/news/lynk-pharmaceuticals-receives-fda-ind-approval-for-brain-penetrant-tyk2-inhibitor-lnk01006-targeting-neuroinflammatory-diseases 2025-12-02T05:26:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lynk-pharmaceuticals-receives-fda-ind-approval-for-brain-penetrant-tyk2-inhibitor-lnk01006-targeting-neuroinflammatory-diseases 2025-12-02T05:26:21+00:00 hourly 0.9 https://trial.medpath.com/news/three-fda-approvals-in-three-months-transform-hereditary-angioedema-treatment-landscape-in-2025 2025-12-02T03:22:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/three-fda-approvals-in-three-months-transform-hereditary-angioedema-treatment-landscape-in-2025 2025-12-02T03:22:01+00:00 hourly 0.9 https://trial.medpath.com/news/belite-bio-raises-350-million-to-advance-retinal-disease-therapies-toward-commercialization 2025-12-02T01:40:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/belite-bio-raises-350-million-to-advance-retinal-disease-therapies-toward-commercialization 2025-12-02T01:40:00+00:00 hourly 0.9 https://trial.medpath.com/news/aptargroup-acquires-brazilian-oral-dosing-specialist-sommaplast-to-expand-pharmaceutical-packaging-capabilities 2025-12-01T22:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aptargroup-acquires-brazilian-oral-dosing-specialist-sommaplast-to-expand-pharmaceutical-packaging-capabilities 2025-12-01T22:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/combination-immunotherapy-shows-promise-for-hiv-control-after-art-discontinuation 2025-12-01T21:31:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/combination-immunotherapy-shows-promise-for-hiv-control-after-art-discontinuation 2025-12-01T21:31:27+00:00 hourly 0.9 https://trial.medpath.com/news/apimeds-pharmaceuticals-merges-with-ai-driven-digital-asset-company-mindwave-in-100m-deal 2025-12-01T21:27:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/apimeds-pharmaceuticals-merges-with-ai-driven-digital-asset-company-mindwave-in-100m-deal 2025-12-01T21:27:01+00:00 hourly 0.9 https://trial.medpath.com/news/eib-and-angelini-ventures-launch-eur150-million-european-biotech-investment-initiative 2025-12-01T21:25:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eib-and-angelini-ventures-launch-eur150-million-european-biotech-investment-initiative 2025-12-01T21:25:00+00:00 hourly 0.9 https://trial.medpath.com/news/juniper-biosciences-secures-40-million-seed-funding-to-advance-radiopharmaceutical-pipeline 2025-12-01T17:39:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/juniper-biosciences-secures-40-million-seed-funding-to-advance-radiopharmaceutical-pipeline 2025-12-01T17:39:59+00:00 hourly 0.9 https://trial.medpath.com/news/faron-pharmaceuticals-appoints-former-astrazeneca-executive-as-cfo-ahead-of-bexmarilimab-registrational-study 2025-12-01T17:35:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/faron-pharmaceuticals-appoints-former-astrazeneca-executive-as-cfo-ahead-of-bexmarilimab-registrational-study 2025-12-01T17:35:49+00:00 hourly 0.9 https://trial.medpath.com/news/kiora-pharmaceuticals-secures-new-patent-for-kio-104-formulations-extending-market-protection-to-2043 2025-12-01T17:31:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kiora-pharmaceuticals-secures-new-patent-for-kio-104-formulations-extending-market-protection-to-2043 2025-12-01T17:31:54+00:00 hourly 0.9 https://trial.medpath.com/news/salarius-pharmaceuticals-partners-with-texas-biomed-to-test-ai-designed-antiviral-against-h5n1-avian-flu 2025-12-01T17:31:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/salarius-pharmaceuticals-partners-with-texas-biomed-to-test-ai-designed-antiviral-against-h5n1-avian-flu 2025-12-01T17:31:23+00:00 hourly 0.9 https://trial.medpath.com/news/recursion-to-present-updated-clinical-data-from-phase-1b-2-trial-of-rec-4881-in-familial-adenomatous-polyposis 2025-12-01T17:31:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/recursion-to-present-updated-clinical-data-from-phase-1b-2-trial-of-rec-4881-in-familial-adenomatous-polyposis 2025-12-01T17:31:01+00:00 hourly 0.9 https://trial.medpath.com/news/promis-neurosciences-validates-plasma-ptau-as-early-predictor-for-alzheimer-s-drug-development 2025-12-01T17:30:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/promis-neurosciences-validates-plasma-ptau-as-early-predictor-for-alzheimer-s-drug-development 2025-12-01T17:30:15+00:00 hourly 0.9 https://trial.medpath.com/news/neonc-s-neo100-shows-enhanced-brain-tumor-efficacy-when-combined-with-ultrasound-in-ai-driven-study 2025-12-01T17:30:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/neonc-s-neo100-shows-enhanced-brain-tumor-efficacy-when-combined-with-ultrasound-in-ai-driven-study 2025-12-01T17:30:12+00:00 hourly 0.9 https://trial.medpath.com/news/regeneron-partners-with-tessera-in-275m-gene-editing-deal-for-alpha-1-antitrypsin-deficiency-treatment 2025-12-01T17:29:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/regeneron-partners-with-tessera-in-275m-gene-editing-deal-for-alpha-1-antitrypsin-deficiency-treatment 2025-12-01T17:29:31+00:00 hourly 0.9 https://trial.medpath.com/news/akebia-therapeutics-establishes-rare-kidney-disease-pipeline-with-two-novel-therapeutic-candidates 2025-12-01T17:29:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/akebia-therapeutics-establishes-rare-kidney-disease-pipeline-with-two-novel-therapeutic-candidates 2025-12-01T17:29:29+00:00 hourly 0.9 https://trial.medpath.com/news/morphocell-technologies-completes-50-million-series-a-to-advance-liver-disease-therapeutics 2025-12-01T17:28:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/morphocell-technologies-completes-50-million-series-a-to-advance-liver-disease-therapeutics 2025-12-01T17:28:10+00:00 hourly 0.9 https://trial.medpath.com/news/keynote-811-trial-shows-pembrolizumab-combination-improves-response-rates-in-her2-positive-gastric-cancer 2025-12-01T17:27:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/keynote-811-trial-shows-pembrolizumab-combination-improves-response-rates-in-her2-positive-gastric-cancer 2025-12-01T17:27:34+00:00 hourly 0.9 https://trial.medpath.com/news/oncoprecision-s-first-in-class-cd64-targeting-adc-onc001-selected-for-oral-presentation-at-ash-2025 2025-12-01T17:26:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/oncoprecision-s-first-in-class-cd64-targeting-adc-onc001-selected-for-oral-presentation-at-ash-2025 2025-12-01T17:26:45+00:00 hourly 0.9 https://trial.medpath.com/news/gsk-presents-long-term-data-supporting-belantamab-mafodotin-and-momelotinib-for-blood-cancers-at-ash-2024 2025-12-01T17:25:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gsk-presents-long-term-data-supporting-belantamab-mafodotin-and-momelotinib-for-blood-cancers-at-ash-2024 2025-12-01T17:25:58+00:00 hourly 0.9 https://trial.medpath.com/news/mabwell-s-anti-st2-antibody-9mw1911-shows-over-40-reduction-in-severe-copd-exacerbations-in-phase-iia-trial 2025-12-01T17:25:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mabwell-s-anti-st2-antibody-9mw1911-shows-over-40-reduction-in-severe-copd-exacerbations-in-phase-iia-trial 2025-12-01T17:25:21+00:00 hourly 0.9 https://trial.medpath.com/news/saga-diagnostics-presents-breakthrough-mrd-data-at-sabcs-2025-demonstrating-100-sensitivity-in-breast-cancer-detection 2025-12-01T17:24:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/saga-diagnostics-presents-breakthrough-mrd-data-at-sabcs-2025-demonstrating-100-sensitivity-in-breast-cancer-detection 2025-12-01T17:24:37+00:00 hourly 0.9 https://trial.medpath.com/news/solid-biosciences-secures-fda-rare-pediatric-disease-designation-for-novel-friedreich-s-ataxia-gene-therapy 2025-12-01T17:24:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/solid-biosciences-secures-fda-rare-pediatric-disease-designation-for-novel-friedreich-s-ataxia-gene-therapy 2025-12-01T17:24:34+00:00 hourly 0.9 https://trial.medpath.com/news/merck-receives-fda-fast-track-designation-for-novel-alzheimer-s-tau-targeting-antibody-mk-2214 2025-12-01T17:23:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/merck-receives-fda-fast-track-designation-for-novel-alzheimer-s-tau-targeting-antibody-mk-2214 2025-12-01T17:23:33+00:00 hourly 0.9 https://trial.medpath.com/news/who-approves-tazbentetol-as-international-name-for-spinogenix-s-first-in-class-synaptic-regenerative-therapy 2025-12-01T17:21:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/who-approves-tazbentetol-as-international-name-for-spinogenix-s-first-in-class-synaptic-regenerative-therapy 2025-12-01T17:21:51+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-isopsa-blood-test-to-reduce-unnecessary-prostate-biopsies 2025-12-01T17:21:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-isopsa-blood-test-to-reduce-unnecessary-prostate-biopsies 2025-12-01T17:21:48+00:00 hourly 0.9 https://trial.medpath.com/news/jacobio-s-kras-g12c-combination-therapy-achieves-71-response-rate-in-first-line-nsclc-trial 2025-12-01T17:21:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/jacobio-s-kras-g12c-combination-therapy-achieves-71-response-rate-in-first-line-nsclc-trial 2025-12-01T17:21:29+00:00 hourly 0.9 https://trial.medpath.com/news/lenz-therapeutics-and-lotus-pharmaceutical-submit-vizz-for-presbyopia-treatment-approval-in-south-korea 2025-12-01T17:21:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lenz-therapeutics-and-lotus-pharmaceutical-submit-vizz-for-presbyopia-treatment-approval-in-south-korea 2025-12-01T17:21:01+00:00 hourly 0.9 https://trial.medpath.com/news/lilly-launches-five-year-real-world-trial-of-tirzepatide-in-uk-primary-care-settings 2025-12-01T17:20:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lilly-launches-five-year-real-world-trial-of-tirzepatide-in-uk-primary-care-settings 2025-12-01T17:20:46+00:00 hourly 0.9 https://trial.medpath.com/news/glial-cell-immune-networks-drive-neuroinflammation-in-glaucomatous-optic-nerve-degeneration 2025-12-01T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/glial-cell-immune-networks-drive-neuroinflammation-in-glaucomatous-optic-nerve-degeneration 2025-12-01T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/bridgebio-pharma-advances-three-potential-first-in-class-therapies-for-rare-diseases 2025-12-01T15:51:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bridgebio-pharma-advances-three-potential-first-in-class-therapies-for-rare-diseases 2025-12-01T15:51:00+00:00 hourly 0.9 https://trial.medpath.com/news/nyxoah-secures-major-cms-reimbursement-increase-for-genio-sleep-apnea-device 2025-12-01T14:14:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nyxoah-secures-major-cms-reimbursement-increase-for-genio-sleep-apnea-device 2025-12-01T14:14:00+00:00 hourly 0.9 https://trial.medpath.com/news/mendus-achieves-large-scale-gmp-manufacturing-milestone-for-vididencel-cell-therapy-in-aml-and-cml 2025-12-01T13:37:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mendus-achieves-large-scale-gmp-manufacturing-milestone-for-vididencel-cell-therapy-in-aml-and-cml 2025-12-01T13:37:10+00:00 hourly 0.9 https://trial.medpath.com/news/protego-biopharma-raises-130m-to-advance-novel-protein-stabilization-approach-for-al-amyloidosis 2025-12-01T13:36:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/protego-biopharma-raises-130m-to-advance-novel-protein-stabilization-approach-for-al-amyloidosis 2025-12-01T13:36:25+00:00 hourly 0.9 https://trial.medpath.com/news/compass-therapeutics-advances-oncology-pipeline-with-pivotal-tovecimig-data-expected-q1-2026 2025-12-01T13:35:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/compass-therapeutics-advances-oncology-pipeline-with-pivotal-tovecimig-data-expected-q1-2026 2025-12-01T13:35:42+00:00 hourly 0.9 https://trial.medpath.com/news/abbvie-s-atogepant-shows-superior-efficacy-in-phase-3-eclipse-trial-for-acute-migraine-treatment 2025-12-01T13:35:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/abbvie-s-atogepant-shows-superior-efficacy-in-phase-3-eclipse-trial-for-acute-migraine-treatment 2025-12-01T13:35:37+00:00 hourly 0.9 https://trial.medpath.com/news/ideaya-biosciences-receives-fda-clearance-for-first-in-class-bispecific-adc-ide034-targeting-multiple-solid-tumors 2025-12-01T13:24:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ideaya-biosciences-receives-fda-clearance-for-first-in-class-bispecific-adc-ide034-targeting-multiple-solid-tumors 2025-12-01T13:24:06+00:00 hourly 0.9 https://trial.medpath.com/news/wockhardt-shares-surge-19-following-fda-acceptance-of-zaynich-antibiotic-application 2025-12-01T13:23:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/wockhardt-shares-surge-19-following-fda-acceptance-of-zaynich-antibiotic-application 2025-12-01T13:23:29+00:00 hourly 0.9 https://trial.medpath.com/news/zentiva-launches-first-biosimilar-monoclonal-antibody-across-eu-markets 2025-12-01T13:23:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/zentiva-launches-first-biosimilar-monoclonal-antibody-across-eu-markets 2025-12-01T13:23:06+00:00 hourly 0.9 https://trial.medpath.com/news/injectable-hiv-treatment-shows-promise-in-african-trial-offering-hope-for-improved-adherence 2025-12-01T09:25:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/injectable-hiv-treatment-shows-promise-in-african-trial-offering-hope-for-improved-adherence 2025-12-01T09:25:55+00:00 hourly 0.9 https://trial.medpath.com/news/enlivex-therapeutics-secures-212-million-funding-for-osteoarthritis-therapy-development-and-digital-asset-strategy 2025-12-01T09:25:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/enlivex-therapeutics-secures-212-million-funding-for-osteoarthritis-therapy-development-and-digital-asset-strategy 2025-12-01T09:25:23+00:00 hourly 0.9 https://trial.medpath.com/news/theia-ventures-leads-pre-seed-funding-for-lemnisca-s-ai-driven-biomanufacturing-platform 2025-12-01T09:25:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/theia-ventures-leads-pre-seed-funding-for-lemnisca-s-ai-driven-biomanufacturing-platform 2025-12-01T09:25:11+00:00 hourly 0.9 https://trial.medpath.com/news/menin-inhibitors-show-promise-as-targeted-therapy-for-aggressive-kmt2a-rearranged-acute-leukemia 2025-12-01T09:23:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/menin-inhibitors-show-promise-as-targeted-therapy-for-aggressive-kmt2a-rearranged-acute-leukemia 2025-12-01T09:23:40+00:00 hourly 0.9 https://trial.medpath.com/news/australian-regulator-updates-safety-warnings-for-glp-1-drugs-over-suicidal-ideation-risk 2025-12-01T05:24:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/australian-regulator-updates-safety-warnings-for-glp-1-drugs-over-suicidal-ideation-risk 2025-12-01T05:24:55+00:00 hourly 0.9 https://trial.medpath.com/news/nitrous-oxide-shows-promise-as-rapid-acting-treatment-for-treatment-resistant-depression 2025-12-01T05:22:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nitrous-oxide-shows-promise-as-rapid-acting-treatment-for-treatment-resistant-depression 2025-12-01T05:22:23+00:00 hourly 0.9 https://trial.medpath.com/news/nevada-health-centers-partners-with-javara-to-expand-clinical-trial-access-including-norovirus-vaccine-study 2025-12-01T05:22:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nevada-health-centers-partners-with-javara-to-expand-clinical-trial-access-including-norovirus-vaccine-study 2025-12-01T05:22:18+00:00 hourly 0.9 https://trial.medpath.com/news/zuellig-pharma-opens-advanced-clinical-trial-support-innovation-center-in-south-korea 2025-12-01T05:22:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/zuellig-pharma-opens-advanced-clinical-trial-support-innovation-center-in-south-korea 2025-12-01T05:22:15+00:00 hourly 0.9 https://trial.medpath.com/news/nanoviricides-submits-orphan-drug-application-for-nv-387-measles-treatment-as-cases-surge-in-us 2025-12-01T02:04:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nanoviricides-submits-orphan-drug-application-for-nv-387-measles-treatment-as-cases-surge-in-us 2025-12-01T02:04:00+00:00 hourly 0.9 https://trial.medpath.com/news/clinical-trial-data-managers-lose-12-hours-weekly-to-manual-tasks-raising-quality-concerns 2025-12-01T01:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/clinical-trial-data-managers-lose-12-hours-weekly-to-manual-tasks-raising-quality-concerns 2025-12-01T01:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/scisparc-acquires-muse-endoscopy-patent-portfolio-to-enter-2-5-billion-gerd-device-market 2025-12-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/scisparc-acquires-muse-endoscopy-patent-portfolio-to-enter-2-5-billion-gerd-device-market 2025-12-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/avandra-health-acquires-datcard-systems-and-sorna-corporation-to-create-world-s-largest-medical-imaging-platform 2025-11-30T17:23:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/avandra-health-acquires-datcard-systems-and-sorna-corporation-to-create-world-s-largest-medical-imaging-platform 2025-11-30T17:23:40+00:00 hourly 0.9 https://trial.medpath.com/news/gut-brain-axis-emerges-as-key-pathway-in-parkinson-s-disease-pathogenesis 2025-11-30T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gut-brain-axis-emerges-as-key-pathway-in-parkinson-s-disease-pathogenesis 2025-11-30T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/cereno-scientific-secures-sek-665-million-financing-to-advance-rare-disease-pipeline-through-2027 2025-11-30T13:22:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cereno-scientific-secures-sek-665-million-financing-to-advance-rare-disease-pipeline-through-2027 2025-11-30T13:22:14+00:00 hourly 0.9 https://trial.medpath.com/news/nigeria-s-niprd-and-futh-lafia-partner-to-advance-local-vaccine-and-drug-development 2025-11-30T05:21:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nigeria-s-niprd-and-futh-lafia-partner-to-advance-local-vaccine-and-drug-development 2025-11-30T05:21:44+00:00 hourly 0.9 https://trial.medpath.com/news/ace2-decoy-receptor-shows-promise-against-multiple-sars-cov-2-variants-in-new-study 2025-11-29T21:24:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ace2-decoy-receptor-shows-promise-against-multiple-sars-cov-2-variants-in-new-study 2025-11-29T21:24:09+00:00 hourly 0.9 https://trial.medpath.com/news/single-2-ml-mirikizumab-injection-demonstrates-bioequivalence-to-two-1-ml-doses-in-healthy-participants 2025-11-29T21:22:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/single-2-ml-mirikizumab-injection-demonstrates-bioequivalence-to-two-1-ml-doses-in-healthy-participants 2025-11-29T21:22:05+00:00 hourly 0.9 https://trial.medpath.com/news/ultrasound-activated-nanocatalysts-trigger-novel-cancer-cell-death-mechanism-in-preclinical-study 2025-11-29T21:21:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ultrasound-activated-nanocatalysts-trigger-novel-cancer-cell-death-mechanism-in-preclinical-study 2025-11-29T21:21:59+00:00 hourly 0.9 https://trial.medpath.com/news/fda-internal-memo-links-10-pediatric-deaths-to-covid-19-vaccination-citing-myocarditis-concerns 2025-11-29T14:25:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-internal-memo-links-10-pediatric-deaths-to-covid-19-vaccination-citing-myocarditis-concerns 2025-11-29T14:25:05+00:00 hourly 0.9 https://trial.medpath.com/news/zura-bio-advances-tibulizumab-phase-2-trials-with-139-million-cash-runway-through-2027 2025-11-29T14:24:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/zura-bio-advances-tibulizumab-phase-2-trials-with-139-million-cash-runway-through-2027 2025-11-29T14:24:04+00:00 hourly 0.9 https://trial.medpath.com/news/novel-hdac2-inhibitor-shows-promise-for-cancer-therapy-despite-acute-toxicity-concerns 2025-11-29T09:23:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-hdac2-inhibitor-shows-promise-for-cancer-therapy-despite-acute-toxicity-concerns 2025-11-29T09:23:13+00:00 hourly 0.9 https://trial.medpath.com/news/dea-finalizes-significant-increases-in-psychedelic-production-quotas-for-2026-to-support-ptsd-and-depression-research 2025-11-29T01:24:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dea-finalizes-significant-increases-in-psychedelic-production-quotas-for-2026-to-support-ptsd-and-depression-research 2025-11-29T01:24:51+00:00 hourly 0.9 https://trial.medpath.com/news/terumo-bct-partners-with-santersus-to-advance-novel-blood-purification-technology-for-sepsis-treatment 2025-11-29T01:23:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/terumo-bct-partners-with-santersus-to-advance-novel-blood-purification-technology-for-sepsis-treatment 2025-11-29T01:23:30+00:00 hourly 0.9 https://trial.medpath.com/news/australian-researchers-identify-romidepsin-as-breakthrough-treatment-for-relapsed-neuroblastoma 2025-11-29T01:22:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/australian-researchers-identify-romidepsin-as-breakthrough-treatment-for-relapsed-neuroblastoma 2025-11-29T01:22:55+00:00 hourly 0.9 https://trial.medpath.com/news/hanmi-pharmaceutical-s-hm16390-shows-dual-mechanism-for-enhanced-cancer-immunotherapy-safety-and-efficacy 2025-11-28T21:24:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hanmi-pharmaceutical-s-hm16390-shows-dual-mechanism-for-enhanced-cancer-immunotherapy-safety-and-efficacy 2025-11-28T21:24:13+00:00 hourly 0.9 https://trial.medpath.com/news/real-world-meta-analysis-confirms-galcanezumab-efficacy-in-migraine-prevention-across-3859-patients 2025-11-28T21:22:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/real-world-meta-analysis-confirms-galcanezumab-efficacy-in-migraine-prevention-across-3859-patients 2025-11-28T21:22:31+00:00 hourly 0.9 https://trial.medpath.com/news/pasithea-therapeutics-secures-60-million-funding-to-advance-mek-inhibitor-for-neurofibromatosis-treatment 2025-11-28T17:30:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pasithea-therapeutics-secures-60-million-funding-to-advance-mek-inhibitor-for-neurofibromatosis-treatment 2025-11-28T17:30:20+00:00 hourly 0.9 https://trial.medpath.com/news/canada-s-drug-agency-recommends-public-reimbursement-for-skyrizi-in-ulcerative-colitis 2025-11-28T17:25:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/canada-s-drug-agency-recommends-public-reimbursement-for-skyrizi-in-ulcerative-colitis 2025-11-28T17:25:56+00:00 hourly 0.9 https://trial.medpath.com/news/novel-biopolymeric-nanocarrier-system-targets-cd44-receptors-for-enhanced-irinotecan-delivery-in-skin-cancer-treatment 2025-11-28T17:25:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-biopolymeric-nanocarrier-system-targets-cd44-receptors-for-enhanced-irinotecan-delivery-in-skin-cancer-treatment 2025-11-28T17:25:39+00:00 hourly 0.9 https://trial.medpath.com/news/veraxa-biotech-s-nasdaq-listing-back-on-track-after-us-government-shutdown-delays 2025-11-28T17:25:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/veraxa-biotech-s-nasdaq-listing-back-on-track-after-us-government-shutdown-delays 2025-11-28T17:25:22+00:00 hourly 0.9 https://trial.medpath.com/news/ge-healthcare-receives-ce-mark-for-revolutionary-total-body-pet-ct-system-and-digital-spect-ct-platform 2025-11-28T17:24:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ge-healthcare-receives-ce-mark-for-revolutionary-total-body-pet-ct-system-and-digital-spect-ct-platform 2025-11-28T17:24:41+00:00 hourly 0.9 https://trial.medpath.com/news/cytiva-and-veeda-lifesciences-establish-host-cell-protein-analysis-center-in-india-to-support-biopharmaceutical-development 2025-11-28T17:23:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cytiva-and-veeda-lifesciences-establish-host-cell-protein-analysis-center-in-india-to-support-biopharmaceutical-development 2025-11-28T17:23:45+00:00 hourly 0.9 https://trial.medpath.com/news/china-s-first-dual-indication-car-t-therapy-receives-nmpa-approval-for-large-b-cell-lymphoma 2025-11-28T17:23:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/china-s-first-dual-indication-car-t-therapy-receives-nmpa-approval-for-large-b-cell-lymphoma 2025-11-28T17:23:07+00:00 hourly 0.9 https://trial.medpath.com/news/profound-medical-launches-ai-powered-bph-module-and-expands-global-reach-through-strategic-partnerships 2025-11-28T17:22:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/profound-medical-launches-ai-powered-bph-module-and-expands-global-reach-through-strategic-partnerships 2025-11-28T17:22:58+00:00 hourly 0.9 https://trial.medpath.com/news/ephb4-targeted-car-t-cell-therapy-enters-phase-i-trial-for-solid-tumors 2025-11-28T13:27:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ephb4-targeted-car-t-cell-therapy-enters-phase-i-trial-for-solid-tumors 2025-11-28T13:27:27+00:00 hourly 0.9 https://trial.medpath.com/news/researchers-engineer-mrna-modified-allogeneic-mscs-for-enhanced-t-cell-immunotherapy 2025-11-28T13:25:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/researchers-engineer-mrna-modified-allogeneic-mscs-for-enhanced-t-cell-immunotherapy 2025-11-28T13:25:43+00:00 hourly 0.9 https://trial.medpath.com/news/lmu-researchers-develop-ai-powered-platform-to-accelerate-rna-drug-carrier-design 2025-11-28T13:25:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lmu-researchers-develop-ai-powered-platform-to-accelerate-rna-drug-carrier-design 2025-11-28T13:25:40+00:00 hourly 0.9 https://trial.medpath.com/news/gene-solutions-launches-ai-powered-spot-mas-multi-cancer-screening-platform-in-taiwan 2025-11-28T13:23:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gene-solutions-launches-ai-powered-spot-mas-multi-cancer-screening-platform-in-taiwan 2025-11-28T13:23:00+00:00 hourly 0.9 https://trial.medpath.com/news/china-approves-first-domestic-il-23p19-antibody-for-psoriasis-treatment 2025-11-28T13:22:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/china-approves-first-domestic-il-23p19-antibody-for-psoriasis-treatment 2025-11-28T13:22:58+00:00 hourly 0.9 https://trial.medpath.com/news/innocare-initiates-global-phase-ii-trial-of-tyk2-inhibitor-soficitinib-for-prurigo-nodularis-treatment 2025-11-28T09:22:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/innocare-initiates-global-phase-ii-trial-of-tyk2-inhibitor-soficitinib-for-prurigo-nodularis-treatment 2025-11-28T09:22:56+00:00 hourly 0.9 https://trial.medpath.com/news/pre-transplant-treg-expansion-therapy-shows-promise-for-reducing-gvhd-risk-in-blood-cancer-patients 2025-11-28T09:21:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pre-transplant-treg-expansion-therapy-shows-promise-for-reducing-gvhd-risk-in-blood-cancer-patients 2025-11-28T09:21:03+00:00 hourly 0.9 https://trial.medpath.com/news/fzocus-1-trial-shows-fuzuloparib-maintenance-therapy-improves-survival-in-advanced-ovarian-cancer 2025-11-28T01:24:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fzocus-1-trial-shows-fuzuloparib-maintenance-therapy-improves-survival-in-advanced-ovarian-cancer 2025-11-28T01:24:17+00:00 hourly 0.9 https://trial.medpath.com/news/bone-metastasis-treatment-pipeline-shows-robust-development-with-10-companies-advancing-novel-therapies 2025-11-28T01:23:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bone-metastasis-treatment-pipeline-shows-robust-development-with-10-companies-advancing-novel-therapies 2025-11-28T01:23:55+00:00 hourly 0.9 https://trial.medpath.com/news/ge-healthcare-receives-fda-authorization-for-ai-powered-3d-mammography-technology 2025-11-28T01:23:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ge-healthcare-receives-fda-authorization-for-ai-powered-3d-mammography-technology 2025-11-28T01:23:41+00:00 hourly 0.9 https://trial.medpath.com/news/northwestern-researchers-develop-reengineered-hpv-vaccine-that-trains-t-cells-to-hunt-cancer 2025-11-28T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/northwestern-researchers-develop-reengineered-hpv-vaccine-that-trains-t-cells-to-hunt-cancer 2025-11-28T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/transgene-secures-eur105-million-to-advance-personalized-cancer-vaccine-platform 2025-11-27T21:24:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/transgene-secures-eur105-million-to-advance-personalized-cancer-vaccine-platform 2025-11-27T21:24:18+00:00 hourly 0.9 https://trial.medpath.com/news/stanford-researchers-demonstrate-cartilage-regeneration-through-gerozyme-inhibition-in-preclinical-studies 2025-11-27T21:22:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/stanford-researchers-demonstrate-cartilage-regeneration-through-gerozyme-inhibition-in-preclinical-studies 2025-11-27T21:22:08+00:00 hourly 0.9 https://trial.medpath.com/news/mbx-biosciences-advances-toward-phase-3-trial-despite-major-investor-exit 2025-11-27T20:42:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mbx-biosciences-advances-toward-phase-3-trial-despite-major-investor-exit 2025-11-27T20:42:00+00:00 hourly 0.9 https://trial.medpath.com/news/maibe-and-leniobio-form-strategic-partnership-to-accelerate-ai-driven-monoclonal-antibody-discovery 2025-11-27T17:24:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/maibe-and-leniobio-form-strategic-partnership-to-accelerate-ai-driven-monoclonal-antibody-discovery 2025-11-27T17:24:21+00:00 hourly 0.9 https://trial.medpath.com/news/moderna-s-mrna-norovirus-vaccine-enters-phase-3-trial-at-newcastle-hospitals 2025-11-27T17:24:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/moderna-s-mrna-norovirus-vaccine-enters-phase-3-trial-at-newcastle-hospitals 2025-11-27T17:24:13+00:00 hourly 0.9 https://trial.medpath.com/news/neuraxpharm-and-mjn-neuro-launch-ai-powered-wearable-device-for-early-epileptic-seizure-detection 2025-11-27T17:20:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/neuraxpharm-and-mjn-neuro-launch-ai-powered-wearable-device-for-early-epileptic-seizure-detection 2025-11-27T17:20:52+00:00 hourly 0.9 https://trial.medpath.com/news/efgartigimod-shows-promise-in-treating-immune-checkpoint-inhibitor-associated-myocarditis-and-myasthenia-gravis 2025-11-27T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/efgartigimod-shows-promise-in-treating-immune-checkpoint-inhibitor-associated-myocarditis-and-myasthenia-gravis 2025-11-27T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/monthly-tezepelumab-injection-enables-severe-asthma-patients-to-discontinue-daily-steroids 2025-11-27T13:26:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/monthly-tezepelumab-injection-enables-severe-asthma-patients-to-discontinue-daily-steroids 2025-11-27T13:26:20+00:00 hourly 0.9 https://trial.medpath.com/news/mendus-reports-positive-2-year-follow-up-data-for-vididencel-immunotherapy-in-high-risk-ovarian-cancer 2025-11-27T13:26:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mendus-reports-positive-2-year-follow-up-data-for-vididencel-immunotherapy-in-high-risk-ovarian-cancer 2025-11-27T13:26:07+00:00 hourly 0.9 https://trial.medpath.com/news/patronus-biotech-secures-gates-foundation-grant-for-novel-multi-stage-malaria-vaccine-development 2025-11-27T13:25:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/patronus-biotech-secures-gates-foundation-grant-for-novel-multi-stage-malaria-vaccine-development 2025-11-27T13:25:32+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-medivir-s-miv-711-orphan-drug-designation-for-osteogenesis-imperfecta-treatment 2025-11-27T13:24:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-medivir-s-miv-711-orphan-drug-designation-for-osteogenesis-imperfecta-treatment 2025-11-27T13:24:58+00:00 hourly 0.9 https://trial.medpath.com/news/gan-lee-pharmaceuticals-launches-phase-3-trial-for-once-monthly-glp-1-receptor-agonist-bofanglutide 2025-11-27T13:24:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gan-lee-pharmaceuticals-launches-phase-3-trial-for-once-monthly-glp-1-receptor-agonist-bofanglutide 2025-11-27T13:24:52+00:00 hourly 0.9 https://trial.medpath.com/news/ema-grants-orphan-drug-designation-to-kedrion-s-ceruloplasmin-treatment-for-rare-iron-metabolism-disorder 2025-11-27T13:23:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ema-grants-orphan-drug-designation-to-kedrion-s-ceruloplasmin-treatment-for-rare-iron-metabolism-disorder 2025-11-27T13:23:14+00:00 hourly 0.9 https://trial.medpath.com/news/fda-withdraws-asbestos-testing-rule-for-talc-cosmetics-plans-revised-proposal 2025-11-27T13:23:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-withdraws-asbestos-testing-rule-for-talc-cosmetics-plans-revised-proposal 2025-11-27T13:23:06+00:00 hourly 0.9 https://trial.medpath.com/news/delphx-capital-markets-completes-c-112000-private-placement-to-support-structured-products-development 2025-11-27T13:14:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/delphx-capital-markets-completes-c-112000-private-placement-to-support-structured-products-development 2025-11-27T13:14:00+00:00 hourly 0.9 https://trial.medpath.com/news/sk-biopharmaceuticals-licenses-wt-7695-radiopharmaceutical-targeting-ca9-for-solid-tumors 2025-11-27T10:23:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sk-biopharmaceuticals-licenses-wt-7695-radiopharmaceutical-targeting-ca9-for-solid-tumors 2025-11-27T10:23:48+00:00 hourly 0.9 https://trial.medpath.com/news/fda-backed-anti-aging-drug-for-dogs-targets-2026-launch-following-efficacy-approval 2025-11-27T08:24:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-backed-anti-aging-drug-for-dogs-targets-2026-launch-following-efficacy-approval 2025-11-27T08:24:22+00:00 hourly 0.9 https://trial.medpath.com/news/chinese-developed-her2-targeting-adc-tqb2102-achieves-77-complete-response-rate-in-phase-ii-breast-cancer-trial 2025-11-27T08:23:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/chinese-developed-her2-targeting-adc-tqb2102-achieves-77-complete-response-rate-in-phase-ii-breast-cancer-trial 2025-11-27T08:23:13+00:00 hourly 0.9 https://trial.medpath.com/news/mhra-approves-inavolisib-for-advanced-hr-positive-her2-negative-breast-cancer 2025-11-27T05:21:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mhra-approves-inavolisib-for-advanced-hr-positive-her2-negative-breast-cancer 2025-11-27T05:21:43+00:00 hourly 0.9 https://trial.medpath.com/news/federal-r-d-budget-cuts-threaten-us-biomedical-innovation-leadership 2025-11-27T03:21:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/federal-r-d-budget-cuts-threaten-us-biomedical-innovation-leadership 2025-11-27T03:21:20+00:00 hourly 0.9 https://trial.medpath.com/news/heartbeam-pursues-multiple-regulatory-paths-after-fda-rejects-12-lead-ecg-synthesis-software-application 2025-11-27T01:29:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/heartbeam-pursues-multiple-regulatory-paths-after-fda-rejects-12-lead-ecg-synthesis-software-application 2025-11-27T01:29:04+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-fast-track-designation-to-zotiraciclib-for-idh-mutant-recurrent-high-grade-glioma 2025-11-27T01:29:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-fast-track-designation-to-zotiraciclib-for-idh-mutant-recurrent-high-grade-glioma 2025-11-27T01:29:02+00:00 hourly 0.9 https://trial.medpath.com/news/imugene-partners-with-jw-therapeutics-to-develop-first-in-class-car-t-combination-for-solid-tumors 2025-11-27T01:27:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/imugene-partners-with-jw-therapeutics-to-develop-first-in-class-car-t-combination-for-solid-tumors 2025-11-27T01:27:37+00:00 hourly 0.9 https://trial.medpath.com/news/arrowhead-pharmaceuticals-soars-23-on-fda-approval-of-redemplo-for-rare-genetic-disease 2025-11-27T01:26:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/arrowhead-pharmaceuticals-soars-23-on-fda-approval-of-redemplo-for-rare-genetic-disease 2025-11-27T01:26:19+00:00 hourly 0.9 https://trial.medpath.com/news/zetagen-therapeutics-raises-12-9m-in-oversubscribed-series-b1-round-following-promising-phase-2a-results-for-breast-cancer-treatment 2025-11-27T01:25:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/zetagen-therapeutics-raises-12-9m-in-oversubscribed-series-b1-round-following-promising-phase-2a-results-for-breast-cancer-treatment 2025-11-27T01:25:34+00:00 hourly 0.9 https://trial.medpath.com/news/kinase-inhibitors-discovered-to-trigger-widespread-protein-degradation-beyond-traditional-inhibition 2025-11-27T01:25:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kinase-inhibitors-discovered-to-trigger-widespread-protein-degradation-beyond-traditional-inhibition 2025-11-27T01:25:32+00:00 hourly 0.9 https://trial.medpath.com/news/engasertib-shows-promise-in-first-controlled-trial-for-hereditary-hemorrhagic-telangiectasia 2025-11-27T01:24:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/engasertib-shows-promise-in-first-controlled-trial-for-hereditary-hemorrhagic-telangiectasia 2025-11-27T01:24:07+00:00 hourly 0.9 https://trial.medpath.com/news/valneva-consolidates-french-operations-closes-nantes-facility-amid-regulatory-setbacks 2025-11-26T21:28:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/valneva-consolidates-french-operations-closes-nantes-facility-amid-regulatory-setbacks 2025-11-26T21:28:12+00:00 hourly 0.9 https://trial.medpath.com/news/missing-prkci-gene-enhances-immunotherapy-response-in-lung-adenocarcinoma-through-senescent-cell-activation 2025-11-26T21:25:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/missing-prkci-gene-enhances-immunotherapy-response-in-lung-adenocarcinoma-through-senescent-cell-activation 2025-11-26T21:25:48+00:00 hourly 0.9 https://trial.medpath.com/news/piramal-pharma-solutions-achieves-full-regulatory-compliance-for-nitrosamine-impurities 2025-11-26T21:24:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/piramal-pharma-solutions-achieves-full-regulatory-compliance-for-nitrosamine-impurities 2025-11-26T21:24:03+00:00 hourly 0.9 https://trial.medpath.com/news/arrowhead-pharmaceuticals-achieves-fda-approval-for-rodemplo-reports-strong-financial-turnaround 2025-11-26T21:22:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/arrowhead-pharmaceuticals-achieves-fda-approval-for-rodemplo-reports-strong-financial-turnaround 2025-11-26T21:22:55+00:00 hourly 0.9 https://trial.medpath.com/news/enveric-biosciences-secures-fourth-patent-for-non-hallucinogenic-neuroplastogenic-drug-candidates 2025-11-26T17:28:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/enveric-biosciences-secures-fourth-patent-for-non-hallucinogenic-neuroplastogenic-drug-candidates 2025-11-26T17:28:45+00:00 hourly 0.9 https://trial.medpath.com/news/mount-sinai-researchers-develop-novel-mrna-therapy-to-combat-antibiotic-resistant-bacterial-infections 2025-11-26T17:26:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mount-sinai-researchers-develop-novel-mrna-therapy-to-combat-antibiotic-resistant-bacterial-infections 2025-11-26T17:26:16+00:00 hourly 0.9 https://trial.medpath.com/news/scisparc-acquires-musetm-endoscopy-patents-to-target-3-billion-gerd-device-market 2025-11-26T17:25:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/scisparc-acquires-musetm-endoscopy-patents-to-target-3-billion-gerd-device-market 2025-11-26T17:25:47+00:00 hourly 0.9 https://trial.medpath.com/news/xoma-royalty-completes-2-035-per-share-acquisition-of-mural-oncology 2025-11-26T17:25:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/xoma-royalty-completes-2-035-per-share-acquisition-of-mural-oncology 2025-11-26T17:25:00+00:00 hourly 0.9 https://trial.medpath.com/news/tangram-therapeutics-advances-novel-rnai-therapy-tgm-312-to-clinical-trials-for-mash-treatment 2025-11-26T17:24:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tangram-therapeutics-advances-novel-rnai-therapy-tgm-312-to-clinical-trials-for-mash-treatment 2025-11-26T17:24:57+00:00 hourly 0.9 https://trial.medpath.com/news/lighthouse-pharmaceuticals-secures-49-2m-nih-grant-for-novel-alzheimer-s-treatment-targeting-bacterial-driver 2025-11-26T17:24:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lighthouse-pharmaceuticals-secures-49-2m-nih-grant-for-novel-alzheimer-s-treatment-targeting-bacterial-driver 2025-11-26T17:24:51+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-novartis-gene-therapy-itvisma-for-spinal-muscular-atrophy-in-older-patients 2025-11-26T17:23:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-novartis-gene-therapy-itvisma-for-spinal-muscular-atrophy-in-older-patients 2025-11-26T17:23:32+00:00 hourly 0.9 https://trial.medpath.com/news/clairity-myriad-genetics-and-magview-launch-first-integrated-ai-genetic-risk-platform-for-breast-cancer-screening 2025-11-26T17:20:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/clairity-myriad-genetics-and-magview-launch-first-integrated-ai-genetic-risk-platform-for-breast-cancer-screening 2025-11-26T17:20:45+00:00 hourly 0.9 https://trial.medpath.com/news/four-gene-signature-predicts-oxaliplatin-response-in-colorectal-cancer 2025-11-26T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/four-gene-signature-predicts-oxaliplatin-response-in-colorectal-cancer 2025-11-26T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/real-world-atopic-dermatitis-patients-often-excluded-from-clinical-trials-study-reveals-safety-differences 2025-11-26T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/real-world-atopic-dermatitis-patients-often-excluded-from-clinical-trials-study-reveals-safety-differences 2025-11-26T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/zymfentra-shows-consistent-efficacy-across-crohn-s-disease-locations-in-post-hoc-analysis-of-liberty-cd-study 2025-11-26T13:23:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/zymfentra-shows-consistent-efficacy-across-crohn-s-disease-locations-in-post-hoc-analysis-of-liberty-cd-study 2025-11-26T13:23:03+00:00 hourly 0.9 https://trial.medpath.com/news/fda-launches-public-input-process-for-bsufa-iv-reauthorization-to-shape-biosimilar-regulatory-framework-through-2032 2025-11-26T09:22:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-launches-public-input-process-for-bsufa-iv-reauthorization-to-shape-biosimilar-regulatory-framework-through-2032 2025-11-26T09:22:44+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-updated-label-for-unloxcyt-based-on-long-term-data-showing-improved-outcomes-in-advanced-cutaneous-squamous-cell-carcinoma 2025-11-26T09:21:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-updated-label-for-unloxcyt-based-on-long-term-data-showing-improved-outcomes-in-advanced-cutaneous-squamous-cell-carcinoma 2025-11-26T09:21:41+00:00 hourly 0.9 https://trial.medpath.com/news/samsung-biologics-reaches-400-global-manufacturing-approvals-reinforcing-cdmo-leadership 2025-11-26T09:21:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/samsung-biologics-reaches-400-global-manufacturing-approvals-reinforcing-cdmo-leadership 2025-11-26T09:21:39+00:00 hourly 0.9 https://trial.medpath.com/news/glenmark-launches-world-s-first-nebulized-triple-therapy-for-copd-treatment 2025-11-26T09:21:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/glenmark-launches-world-s-first-nebulized-triple-therapy-for-copd-treatment 2025-11-26T09:21:03+00:00 hourly 0.9 https://trial.medpath.com/news/galux-secures-29-million-series-b-to-advance-ai-driven-protein-design-platform 2025-11-26T09:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/galux-secures-29-million-series-b-to-advance-ai-driven-protein-design-platform 2025-11-26T09:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/abbott-initiates-voluntary-correction-for-3-million-freestyle-libre-3-glucose-sensors-following-false-low-reading-reports 2025-11-26T05:24:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/abbott-initiates-voluntary-correction-for-3-million-freestyle-libre-3-glucose-sensors-following-false-low-reading-reports 2025-11-26T05:24:04+00:00 hourly 0.9 https://trial.medpath.com/news/long-acting-donepezil-depot-injection-shows-promise-for-canine-cognitive-dysfunction-treatment 2025-11-26T05:22:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/long-acting-donepezil-depot-injection-shows-promise-for-canine-cognitive-dysfunction-treatment 2025-11-26T05:22:55+00:00 hourly 0.9 https://trial.medpath.com/news/chugai-pharmaceutical-and-biomy-partner-to-develop-ai-powered-cancer-pathology-diagnostic-support-programs 2025-11-26T05:22:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/chugai-pharmaceutical-and-biomy-partner-to-develop-ai-powered-cancer-pathology-diagnostic-support-programs 2025-11-26T05:22:38+00:00 hourly 0.9 https://trial.medpath.com/news/fda-extends-review-timeline-for-ascendis-pharma-s-achondroplasia-treatment-to-february-2026 2025-11-26T01:26:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-extends-review-timeline-for-ascendis-pharma-s-achondroplasia-treatment-to-february-2026 2025-11-26T01:26:25+00:00 hourly 0.9 https://trial.medpath.com/news/chugai-s-port-delivery-system-with-ranibizumab-shows-promise-in-japanese-phase-i-ii-trial-for-retinal-diseases 2025-11-26T01:23:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/chugai-s-port-delivery-system-with-ranibizumab-shows-promise-in-japanese-phase-i-ii-trial-for-retinal-diseases 2025-11-26T01:23:38+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-reformulated-ranitidine-after-five-year-market-absence-due-to-carcinogen-concerns 2025-11-26T01:23:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-reformulated-ranitidine-after-five-year-market-absence-due-to-carcinogen-concerns 2025-11-26T01:23:28+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-first-accelerated-approval-for-novel-iga-nephropathy-treatment-voyxact 2025-11-26T01:22:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-first-accelerated-approval-for-novel-iga-nephropathy-treatment-voyxact 2025-11-26T01:22:23+00:00 hourly 0.9 https://trial.medpath.com/news/real-world-study-reveals-higher-than-expected-atrial-fibrillation-risk-with-mavacamten-in-hypertrophic-cardiomyopathy-patients 2025-11-26T00:01:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/real-world-study-reveals-higher-than-expected-atrial-fibrillation-risk-with-mavacamten-in-hypertrophic-cardiomyopathy-patients 2025-11-26T00:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/novel-intravaginal-mrna-platform-delivers-enhanced-hiv-protection-through-localized-antibody-production 2025-11-25T21:30:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-intravaginal-mrna-platform-delivers-enhanced-hiv-protection-through-localized-antibody-production 2025-11-25T21:30:17+00:00 hourly 0.9 https://trial.medpath.com/news/canada-s-1-5-billion-rare-disease-strategy-shows-early-success-with-nine-life-saving-treatments 2025-11-25T21:27:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/canada-s-1-5-billion-rare-disease-strategy-shows-early-success-with-nine-life-saving-treatments 2025-11-25T21:27:37+00:00 hourly 0.9 https://trial.medpath.com/news/novartis-restructures-swiss-operations-with-550-job-cuts-while-investing-80m-in-rna-therapy-production 2025-11-25T21:27:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novartis-restructures-swiss-operations-with-550-job-cuts-while-investing-80m-in-rna-therapy-production 2025-11-25T21:27:16+00:00 hourly 0.9 https://trial.medpath.com/news/gilead-acquires-sprint-bioscience-s-trex1-cancer-program-in-414-million-deal 2025-11-25T21:24:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gilead-acquires-sprint-bioscience-s-trex1-cancer-program-in-414-million-deal 2025-11-25T21:24:32+00:00 hourly 0.9 https://trial.medpath.com/news/lixte-biotechnology-acquires-liora-technologies-light-proton-therapy-system-for-cancer-treatment 2025-11-25T21:24:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lixte-biotechnology-acquires-liora-technologies-light-proton-therapy-system-for-cancer-treatment 2025-11-25T21:24:27+00:00 hourly 0.9 https://trial.medpath.com/news/apatinib-plus-chemotherapy-extends-progression-free-survival-in-advanced-osteosarcoma-phase-ii-trial 2025-11-25T21:24:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/apatinib-plus-chemotherapy-extends-progression-free-survival-in-advanced-osteosarcoma-phase-ii-trial 2025-11-25T21:24:15+00:00 hourly 0.9 https://trial.medpath.com/news/ceribell-receives-fda-clearance-for-ai-powered-seizure-detection-in-neonates 2025-11-25T21:23:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ceribell-receives-fda-clearance-for-ai-powered-seizure-detection-in-neonates 2025-11-25T21:23:14+00:00 hourly 0.9 https://trial.medpath.com/news/zanidatamab-demonstrates-durable-responses-in-her2-positive-biliary-tract-cancer-earns-fda-accelerated-approval 2025-11-25T21:23:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/zanidatamab-demonstrates-durable-responses-in-her2-positive-biliary-tract-cancer-earns-fda-accelerated-approval 2025-11-25T21:23:07+00:00 hourly 0.9 https://trial.medpath.com/news/new-market-analysis-reveals-global-monkeypox-clinical-trial-landscape-and-strategic-investment-opportunities 2025-11-25T21:21:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/new-market-analysis-reveals-global-monkeypox-clinical-trial-landscape-and-strategic-investment-opportunities 2025-11-25T21:21:13+00:00 hourly 0.9 https://trial.medpath.com/news/xenon-pharmaceuticals-to-present-long-term-azetukalner-data-at-aes-2025-highlighting-extended-seizure-freedom 2025-11-25T17:32:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/xenon-pharmaceuticals-to-present-long-term-azetukalner-data-at-aes-2025-highlighting-extended-seizure-freedom 2025-11-25T17:32:46+00:00 hourly 0.9 https://trial.medpath.com/news/sarepta-receives-fda-approval-for-enhanced-elevidys-gene-therapy-trial-in-non-ambulatory-duchenne-patients 2025-11-25T17:29:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sarepta-receives-fda-approval-for-enhanced-elevidys-gene-therapy-trial-in-non-ambulatory-duchenne-patients 2025-11-25T17:29:56+00:00 hourly 0.9 https://trial.medpath.com/news/adalyon-appoints-former-novo-nordisk-director-as-ceo-to-advance-ai-powered-speech-biomarkers-for-clinical-trials 2025-11-25T17:29:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/adalyon-appoints-former-novo-nordisk-director-as-ceo-to-advance-ai-powered-speech-biomarkers-for-clinical-trials 2025-11-25T17:29:10+00:00 hourly 0.9 https://trial.medpath.com/news/innova-therapeutics-acquires-enci-therapeutics-to-advance-first-in-class-sfrp2-targeting-cancer-antibody 2025-11-25T17:28:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/innova-therapeutics-acquires-enci-therapeutics-to-advance-first-in-class-sfrp2-targeting-cancer-antibody 2025-11-25T17:28:28+00:00 hourly 0.9 https://trial.medpath.com/news/who-approves-international-name-for-os-therapies-osteosarcoma-immunotherapy-ahead-of-regulatory-submissions 2025-11-25T17:28:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/who-approves-international-name-for-os-therapies-osteosarcoma-immunotherapy-ahead-of-regulatory-submissions 2025-11-25T17:28:10+00:00 hourly 0.9 https://trial.medpath.com/news/novo-nordisk-s-amycretin-shows-promising-phase-2-results-in-type-2-diabetes-advances-to-phase-3-trials 2025-11-25T17:26:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novo-nordisk-s-amycretin-shows-promising-phase-2-results-in-type-2-diabetes-advances-to-phase-3-trials 2025-11-25T17:26:46+00:00 hourly 0.9